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Bacillus Calmette-Guérin (BCG), the only currently licensed tuberculosis (TB) 
vaccine, provides variable efficacy. Despite the use of BCG, TB remains a global 
health problem. BCG is administered at birth; however, more than 15% of infants 
are born preterm [PT (<37 weeks gestation)], or have low birth weights [LBW 
(<2,500g)], with >90% of these born in developing countries, where the majority 
of TB cases are found. It is not known how birth weight at the time of vaccination 
may affect the BCG-induced immune response and subsequent protection 
against TB. We hypothesised that BCG-vaccinated PT and LBW infants would 
have a qualitatively and quantitatevely less optimal immune response, compared 
to term or normal birth weight (NBW) infants.  
We designed a study to determine the effects of birth weight and maturity 
on BCG induced T cell responses, thought to be important mediators in 
protection against TB. We enrolled healthy infants BCG vaccinated at birth and 
stratified by birth weight, gestational age (GA), size for GA and gender. At 10 
weeks of age, a whole blood intracellular cytokine assay was performed and 
complemented by assessment of the proliferative potential of BCG-specific T 
cells from a 6-day Ki67 proliferation assay. Multiparameter flow cytometry was 
used to measure BCG-specific T cell responses in these two assay systems. 
This is the first detailed analysis of the functional capacity of BCG-induced T cell 
responses in PT and LBW infants. 
We found that LBW infants had a lower proportion of polyfunctional BCG-
specific CD4+ T cells and corresponding higher proportions of single cytokine-
producing CD4+ T cells expressing IFN- only, compared to NBW infants. No 
differences were found in the proliferative potential of BCG-specific T cells. Our 
results suggest that birth weight at time of vaccination may affect the quality of 
the BCG-induced immune response, and warrant further investigation in larger 
cohorts. These results may ultimately have important implications for neonatal 
BCG vaccination practices worldwide.   
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Figure 1.1. Naïve CD4 T cell differentiation into different T-cell effector subsets. 
Differentiation depends on the type of APC and cytokines in the 
microenvironment of the cell (arrows). The different T cell subsets express 
specific transcription factors (shown within the cell) and certain signature 
cytokines (Adapted from Bonilla and Oettegen 2010).  
 
Figure 1.2. Regulatory T cells and the different immune functions they modulate 
(Sojka, Huang et al. 2008)  
 
Figure 1.3. Estimated rates of new TB cases worldwide in 2008. (Adapted from 
the WHO; Global Tuberculosis control: a short update to the 2009 report). 
 
Figure 3.1 Flow cytometry gating strategy and representative data from the 
whole blood intracellular cytokine staining (WB-ICC) assay. (A) Gating is first 
performed on singlets then lymphocytes, followed by CD3+ T cells, from which 
CD4+ and CD8+ T cells are differentiated. In (B) the percentage of CD4+ T cells 
expressing combinations of IL-2, IFN- , TNF-  or IL-17 cytokines are shown for a 
low birth weight (LBW) and normal birth weight (NBW) infant; percentages shown 
on the plots are prior to subtraction of cytokine production in the negative control 
sample. Representative data are shown from a negative control (unstimulated), 
BCG and SEB stimulated sample.  
 
Figure 3.2. (A) Frequency of BCG-specific CD4+ T cells expressing cytokines in 
LBW (n=52) and NBW (n=53) infants. The horizontal line represents the median 
 xiv 
and the boxes represent the interquartile range. The Mann Whitney test was 
used to calculate statistical differences between individual groups. (B) The 
percentage of vaccinated infants with a detectable BCG-specific CD4+ T cell 
response above background. Out of 52 LBW and 53 NBW infants, CD4+ T cells 
from 50 LBW (96%) and 53 NBW (100%) infants responded to BCG. There was 
no statistical difference between the percentages of infants responding to BCG 
(Fisher’s exact test). 
 
Figure 3.3. Correlation between the birth weight of 105 BCG vaccinated infants 
and the frequency of BCG-specific CD4+ T cells expressing either: (A) IL-2, (B) 
IFN- , (C) TNF-  or (D) IL-17. Statistical significance was calculated using the 
Spearman test. 
 
Figure 3.4. Correlation between the gestational ages of 105 BCG vaccinated 
infants and frequency of BCG-specific CD4+ T cells expressing either: (A) IL-2, 
(B) IFN- , (C) TNF-  or (D) IL-17. Statistical significance was calculated using the 
Spearman test. 
 
Figure 3.5. The frequency and proportion of BCG-specific CD4+ T cells 
expressing combinations of IL-2, IFN- , TNF-  or IL-17 in LBW and NBW infants. 
The frequency (A) of CD4+ T cells expressing combinations of cytokines for all 
infants is shown (LBW, n=52 and NBW, n=53 respectively). Only infants with a 
detectable BCG-specific CD4+ T cell response above background (LBW, n=50 
and NBW, n=53; see Materials and Methods, 2.2.8) were included when 
calculating the proportion of BCG-specific CD4+ T cells expressing each 
combination of cytokines (B). The horizontal line represents the median and the 
boxes represent the interquartile range. Each pie is divided into 3 slices that 
represent the median proportion of the total BCG-specific CD4+ T cell response, 
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a slice each for T cells expressing a combination of 3, 2 or 1 cytokine only (B).  
The Mann Whitney test was used to calculate statistical significance between the 
individual groups. 
 
Figure 3.6. Proportions of polyfunctional BCG-specific CD4+ T cells stratified by 
size for gestational age, term status, and sex. The proportions of BCG-specific 
CD4+ T cells co-expressing IL-2, IFN-  and TNF-  cytokines together (A), co-
expressing IFN-  and TNF-  cytokines only (B), or expressing IFN-  only (C) are 
shown. Only infants that responded to BCG are shown and were stratified as 
follows: small for gestational age (SGA; n=42), appropriate for gestational age 
(AGA; n=47), large for gestational age (LGA; n=14), term (n=65), preterm (n=38), 
male (n=51) and female (n=52). The horizontal line represents the median and 
the boxes represent the interquartile range. The Mann Whitney test was used for 
comparisons between two groups, and the Kruskal-Wallis test was used for 
comparisons of three groups. 
 
Figure 3.7. (A) Frequency of BCG-specific CD8+ T cells expressing cytokines in 
LBW and NBW infants. The horizontal line represents the median and the boxes 
represent the interquartile range. There was no statistical difference as 
determined by the Mann Whitney test. (B) The percentage of vaccinated infants 
with a detectable BCG-specific CD8+ T cell response above background levels. 
Out of a total of 105 infants, 39 LBW (75%) and 41 NBW (77%) infants had a 
detectable CD8+ T cell response to BCG. There was no statistical difference 
between the percentages of infants responding to BCG (Fisher’s exact test). 
 
Figure 3.8. Correlation between the birth weight of 105 BCG vaccinated infants 
and the frequency of BCG-specific CD8+ T cells expressing either IL-2 (A), IFN-
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(B), TNF-  (C), or IL-17 (D). Statistical significance was calculated using the 
Spearman test. 
 
Figure 3.9. The frequency (A) and proportion (B) of BCG-specific CD8+ T cells 
expressing combinations of IL-2, IFN- , TNF-  or IL-17 cytokines in LBW and 
NBW infants. Only infants with a detectable BCG-specific CD8+ T cell response 
above background (LBW, n=39 and NBW, n=41) were included in the proportions 
of the total BCG-specific CD8+ T cell response shown in (B). The horizontal line 
represents the median and the boxes represent the interquartile range. Each pie 
is divided into 3 slices that represent the median proportion of the total BCG-
specific CD8+ T cell response, a slice each for T cells expressing a combination 
of 3, 2 or 1 cytokine only (B). Statistical analyses were determined by the Mann 
Whitney test.  
 
Figure 4.1. Flow cytometry gating strategy and analysis of lymphocyte viability in 
the Ki67 and Oregon Green (OG) proliferation assays. Cryopreserved PBMC 
were thawed and cultured with BCG, SEB or medium (UNS; unstimulated) in 
either a 6-day Ki67 proliferation assay (without OG), or a 6-day OG-based 
proliferation assay (see Materials and Methods, 2.2.5). (A) Gating is first 
performed on singlets then on live lymphocytes by gating on ViViDlow CD3+ cells, 
from which total CD3+ T cells are differentiated into CD3+CD8+ and CD3+CD8- 
T cell subsets. This is followed by gating on CD8+ and CD8- OGlow (B) or CD8+ 
and CD8- Ki67+ (C) proliferating cells. CD4+ T cells were defined as CD3+CD8- 
lymphocytes. Representative data are shown from a BCG stimulated sample. (D) 
Frequency of viable CD3+ T cells gated on ViViDlow CD3+ live cells from Ki67 
(n=7) and OG (n=14) proliferation assays. The horizontal line represents the 
median; the Mann Whitney test was used for comparisons between two groups. 
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Figure 4.2. Kinetics of Ki67 expression in proliferating T cells over 6 days. 
Cryopreserved PBMC were thawed and cultured with BCG or medium only 
(unstimulated) in a 6-day Ki67 proliferation assay (see Materials and Methods, 
2.2.5). Representative dot plots of proliferating CD8-Ki67+ live cells from one 
infant incubated with medium only or BCG and quantified on days 2, 4 and 6 are 
shown (A). The frequency of proliferating CD8- Ki67+ live cells incubated with 
medium only (B) or BCG (C) were quantified on days 2, 4 and 6 by 
multiparameter flow cytometry. CD4+ T cells were defined as CD3+CD8- 
lymphocytes. Data shown are from 5 infants. Dot plots shown are from one infant 
and data are shown as a percentage of CD4+ T cells. 
 
Figure 4.3. Proliferative response of BCG-specific Ki67+CD4+ and CD8+ T cells 
in LBW (n=20) and NBW (n=20) infants. Proliferative response is expressed as a 
stimulation index (SI). The horizontal line represents the median. Statistical 
differences between the proliferative BCG-specific T cell responses were 
determined by the Mann Whitney test. 
 
Figure 4.4. Correlation between BCG-specific T cell proliferation and birth 
weight. (A) Correlation between BCG-specific Ki67+CD4+ T cell expression and 
birth weight (n=40). (B) Correlation between BCG-specific Ki67+CD8+ T cell 
expression and birth weight (n=40). Statistical analyses were determined by the 
Spearman test. 
 
Figure 4.5. Cytokine production capacity of BCG-specific proliferating CD4+ T 
cells. Cryopreserved PBMC were cultured for 6 days with BCG, SEB or medium 
(UNS; unstimulated) (see Materials and Methods, 2.2.5). To detect cytokine 
expression, cells were restimulated for 5 hrs on day 6 with PMA and ionomycin 
(PMA/I) and analyzed by flow cytometry. Cells gated on proliferating CD3+CD8- 
 xviii 
Ki67+ live cells were differentiated into T cells expressing combinations of IL-2, 
IFN-  or TNF- . CD4+ T cells were defined as CD3+CD8- lymphocytes. (A) 
Representative dot plots of cytokine expressing cells gated on live CD4+ 
proliferating cells in one LBW and NBW infant are shown. Percentages shown on 
the plots are prior to subtraction of cytokine production in the PMA/I negative 
control sample. The percentage of BCG-specific CD4+ T cells expressing 
cytokines in LBW (n=18) and NBW (n=18) infants is shown in (B). The data is 
shown as the frequency of grandparent (see Materials and Methods, 2.2.7). The 
horizontal line represents the median and the boxes represent the interquartile 
range. Data shown in (B) and (C) are after background subtraction of the PMA/I 
negative control sample (see Materials and Methods, 2.2.8). Statistical analyses 
were determined by the Mann Whitney test.  
 
Figure 4.6. The frequency (A) and proportion (B) of proliferating BCG-specific 
CD4+ T cells expressing combinations of IL-2, IFN-  or TNF-  cytokines in LBW 
and NBW infants. Data shown are after background subtraction of the PMA/I 
negative control sample, and only infants who met criteria for a positive response 
and minimum numbers of viable CD3+ cells are shown (LBW, n=18 and NBW, 
n=18) (see Materials and Methods, 2.2.8). The data is shown as the frequency of 
grandparent (see Materials and Methods, 2.2.7). CD4+ T cells were defined as 
CD3+CD8- lymphocytes. The horizontal line represents the median and the 
boxes represent the interquartile range. Each pie is divided into 4 slices that 
represent the median proportion of the total BCG-specific CD4+ T cell response, 
a slice each for proliferating T cells that are not expressing any cytokines, or a 
combination of 3, 2 or 1 cytokine only (B). Statistical analyses were determined 
by the Mann Whitney test.  
 
Figure 4.7. Cytokine production capacity of BCG-specific proliferating CD8+ T 
cells. Cryopreserved PBMC were cultured for 6 days with BCG, SEB or medium 
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(UNS; unstimulated), restimulated for 5 hrs on day 6 PMA/I and analyzed by flow 
cytometry (see Materials and Methods, 2.2.5). Cells gated on proliferating 
CD3+CD8+ Ki67+ live cells were differentiated into T cells expressing 
combinations of IL-2, IFN-  or TNF- . (A) Representative dot plots of cytokine 
expressing cells gated on live CD3+CD8+ proliferating cells in one LBW and 
NBW infant are shown. Percentages shown on the plots are prior to subtraction 
of cytokine production in the PMA/I negative control sample. (B) Frequency of 
BCG-specific CD8+ T cells that are proliferating and expressing cytokines in 
LBW and NBW infants. The data is shown as the frequency of grandparent (see 
Materials and Methods, 2.2.7). The horizontal line represents the median and the 
boxes represent the interquartile range. There was no statistical difference as 
determined by the Mann Whitney test. 
 
Figure 4.8. The frequency (A) and proportion (B) of BCG-specific CD8+ T cells 
that are proliferating and expressing combinations of IL-2, IFN-  or TNF-  
cytokines in LBW and NBW infants. Data shown are after background subtraction 
of the PMA/I negative control sample, and only infants who met criteria for a 
positive response and minimum numbers of viable CD3+ cells are shown (LBW, 
n=16 and NBW, n=16) (see Materials and Methods, 2.2.8). The data is shown as 
the frequency of grandparent (see Materials and Methods, 2.2.7). The horizontal 
line represents the median and the boxes represent the interquartile range. Each 
pie is divided into 4 slices that represent the median proportion of the total BCG-
specific CD8+ T cell response, a slice each for T cells that are not expressing 
any cytokines, or a combination of 3, 2 or 1 cytokine only (B). Statistical analyses 
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Immunity to infection involves the ability of the host to recognise and promptly act 
to clear invading pathogens. The relevant arm of the immune system acts to 
prevent infection of either intracellular or extracellular pathogens. In the following 
sections, characteristics of both innate and adaptive immunity will be described in 
more detail. After gaining this foundation in immunology, the concept of inducing 
and manipulating the immune system through vaccination to protect against 
infection will be introduced. Focus will then be on tuberculosis (TB) disease, the 
TB vaccine and reasons why, despite its widespread use, TB has become an 
epidemic. Lastly, an overview of the neonatal immune system and early life 
vaccines will be presented, illustrating how host factors such as birth weight and 
maturity may potentially modulate vaccine-induced immune responses. 
  
1.2 The innate immune system 
The innate immune system is the first line of defence against invading 
pathogens. It is rapid, non-specific and innate in the sense that most responses 
are not affected or enhanced by prior exposure, and innate immune cells are 
present prior to encounter with pathogen. Innate responses can be divided into 2 
phases. The first, simplest and immediate form of innate immunity is preventing 
the pathogen from entering the host. The skin is the major line of defence and 
acts as a barrier when intact. Most pathogens fail to survive on the surface of the 
skin due to the low pH of sweat and sebaceous secretions. In addition, most 
bodily secretions have antimicrobial properties, such as saliva and tears 
containing lysozyme, acidic gastric juice, and milk containing lactoperoxidase. 
Mucus secretions prevent the pathogen from adhering to epithelial cells and 
mechanical action such as ciliary movement and coughing expel pathogens. 
Another mode of action is that of microbial antagonism, commensal organisms 
flourishing in the host suppress pathogens by producing antimicrobial 
compounds or by outcompeting pathogens for essential resources. However, if 
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these external barriers fail to prevent infection then the second phase of innate 
immunity comes into play. (Janeway 2005; Rabson, Roitt et al. 2005; Chaplin 
2010)  
A pathogen that enters the host may, in some cases, be directly cleared 
by complement. Complement is a system of plasma proteins present at all times 
that defend against infection, in particular against extracellular bacteria. In the 
classical pathway the complement system is activated when antibodies bound to 
the surface of a pathogen bind the complement component C1. A sequence of 
cleavage reactions ultimately leads to a C3/C5 convertase enzyme made up of 
the complement components C4b,2b which cleave the most abundant 
complement component C3 to C3b. C3b then binds to the surface of bacteria to 
form a complex that favours its uptake and destruction by phagocytic cells in a 
process known as opsonisation. There is also an enzymatic molecular cascade 
leading to the formation of a membrane attack complex (MAC) made up of the 
terminal complement components C6-C9. The MAC can insert directly into the 
lipid bilayer of target cells creating pores leading to direct lysis of the pathogen. 
In the alternative complement pathway, activation is not dependent on Ab but on 
bound C3b from the classical pathway. Bound C3b binds factor B which in turn is 
cleaved by protease factor D into Ba and Bb. The C3b,Bb complex of the 
alternative pathway forms the C3/C5 convertase enzyme which is different but 
homologous to the C4b,2b complex of the classical pathway. The C3/C5 
convertase enzyme of the alternative pathway enhances the effects of the 
classical pathway by addition of C3b onto the surface of bacteria. Most bacteria 
are resistant to complement and can activate the phagocytic cells such as 
macrophages, which in turn activate acute phase protein (APP) production in the 
liver. These proteins are non-specific and bind to a wide range of 
microorganisms. Binding of APP to the surface of bacteria enhances complement 
binding and subsequent destruction by macrophages in the liver (Janeway 2005; 
Rabson, Roitt et al. 2005; Chaplin 2010). 
 4 
Natural killer (NK) cells and phagocytic cells such as dendritic cells (DCs) 
macrophages, monocytes and neutrophils are the major cell types involved in 
innate immunity. Receptors on NK cells recognise virally infected or tumor cells 
lacking major histocompatibility complex (MHC) class  molecules. These cells 
are killed either by apoptosis (programmed cell death) through release of 
cytotoxic granules or the FAS/FasL (Fas-ligand) pathway (Rabson, Roitt et al. 
2005). Phagocytic cells on the other hand have pattern recognition receptors 
(PRRs) that recognise and adhere to pathogen-associated molecular patterns 
(PAMPS) on the surface of pathogens. These PAMPs are not found in the host 
and binding to PRRs activates phagocytic cells to ingest and destroy the 
pathogen. Phagocytic cells produce reactive oxygen species (ROS) and nitric 
oxide (NO) that are cytotoxic to both bacteria and viruses. They also produce the 
cytokine interleukin (IL)-12 important in initiating the differentiation of naïve CD4 
T cells to become Th1 cells. Phagocytic cells then bind peptides from ingested 
pathogens or antigens (Ags) in the context of MHC class  and class  
molecules. When these phagocytic cells migrate from infection sites to draining 
lymphoid organs, the bound peptides are presented to cognate T cells thus 
activating adaptive immunity. A family of transmembrane proteins known as toll-
like receptors (TLRs) found on phagocytic cells but primarily on DCs can also 
recognise PAMPs and appear to control the type of defensive mechanism 
initiated. Unlike general phagocytic cells, DCs are professional Ag presenting 
cells (APCs) that can prime naïve T cells. Activation of TLRs triggers DCs in 
particular to express proinflammatory cytokine such as tumor necrosis factor 
(TNF) and interferon  (IFN- ), which may ultimately lead to the activation of 
adaptive immunity. In addition DCs are important producers of chemokines that 
attract T cells (Janeway 2005; Rabson, Roitt et al. 2005; Chaplin 2010). 
For years it was widely believed that the innate immune system 
responded in a similar way each time it encountered a pathogen without 
developing immunological memory, a feature attributed to adaptive immunity. 
However, recent studies have suggested that NK cells develop immunological 
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memory (O'Leary, Goodarzi et al. 2006; Sun, Beilke et al. 2009), as shown for 
example in the model of mice cytomegalovirus (MCMV) infection where NK cells 
are known to be protective. NK cells from cytomegalovirus (CMV) challenged 
mice adoptively transferred to naïve mice expanded and cleared infection more 
rapidly upon secondary CMV challenge (Sun, Beilke et al. 2009). 
 
1.3 The adaptive immune system 
Many pathogens have evolved mechanisms to evade detection by innate 
immunity, such as modulation of surface molecules to prevent binding of 
complement and release of antiphagocytic surface molecules and exotoxins 
(Rabson, Roitt et al. 2005). The solution to this was the host evolution and 
development of the adaptive arm of the immune response, which can be divided 
into humoral (antibody) and cell-mediated responses. Immunological memory, 
the ability to mount a more efficient and rapid response upon secondary 
encounter with Ag/pathogen, is the hallmark of adaptive immunity (Janeway 
2005; Chaplin 2010). 
 
1.3.1 Humoral response 
The main effector cells of the humoral response of adaptive immunity are B-
lymphocytes. Millions of B-lymphocytes are produced in the bone marrow, each 
making only one type of antibody (Ab) with specificity for only one Ag. Antibodies, 
also known as immunoglobins (Ig) are encoded by multiple gene segments for 
heavy chains,  light chains and  light chains. Ab production defines B cells. 
The basic Ig structural unit is composed of 2 heavy chains and 2 light chains. 
The heavy and light chains consist of variable amino acid terminal regions 
designated as VH, V  and V  respectively. These have sub-regions that are 
hypervariable forming the Ag binding domain of each Ab. Hypervariable regions 
allow Ab to specifically recognise a wide array of different Ag. The carboxyl 
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terminal end of each heavy and light chain is constant with 2 heavy chains 
forming the Fc domain. The Fc domain can bind to cell-surface Fc receptors and 
is important in activating the complement system. Human Igs are divided into 5 
major classes, IgG, IgA, IgM, IgD and IgE, based on the heavy chain constant 
region. Class switching within germinal centres from IgM and IgD to other 
classes can occur in an active process of gene mutation that result in changes 
within the Ag binding domain. Cytokines can partly promote class switching, for 
example IL-4 and IL-13 to IgE and IL-10 and TGF-  to IgA. Mutations that result 
in increased Ab affinity for a particular Ag results in the B cell producing that Ab 
gaining a proliferative advantage within a B cell pool when that particular Ag is 
encountered again. This is called affinity maturation and that B cell proliferates to 
dominate the pool of responding cells (Rabson, Roitt et al. 2005; Bonilla and 
Oettgen 2010; Chaplin 2010).  
Antibodies (Abs) expressed on the surface of each B-lymphocytes act as 
receptors for pathogen antigens (Ag). In this primary response, Ab that correctly 
binds to Ag causes clonal proliferation of that particular B cell and differentiation 
into Ab producing plasma and/or memory B cells. The primary response is slow 
and leads to proliferation of short lived, low affinity Ab with other isotypes of 
higher affinity appearing only later. Memory B cells are long-lived B cells that 
require fewer cycles to clonally expand into effectors. During secondary 
encounter to the same Ag (secondary response), memory B cells are activated 
resulting in a more rapid response and abundant Ab production of higher affinity 
(affinity maturation) compared to the primary response. As each B cell makes 
only one type of specific Ab, plasma cells will produce Ab of one type and 
specificity. Thus Ag induces clonal selection of plasma cells producing Ab 
specific to that particular Ag. Once Ab binds Ag it induces the complement 
system, and enhances phagocytosis (opsonisation) leading to clearance of the 
Ag. Circulating Abs can also bind and neutralise antiphagocytic surface 
molecules and exotoxins. This is important to neutralise pathogens that evade 
complement system and to neutralise toxins that may otherwise damage tissue. 
(Bonilla and Oettgen 2010; Chaplin 2010). 
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1.3.2 Cell-mediated response 
The humoral response cannot directly target intracellular pathogens. Thus the 
host developed cell-mediated adaptive immunity to counter intracellular infection. 
Unlike B cells produced in the bone marrow, the main effectors of cell-mediated 
adaptive immunity are produced in the thymus gland and are thus called T cells. 
The T cell receptor (TCR) of naïve T cells, which is analogous to B cell Ag 
receptors, recognizes Ag presented by major histocompatibility complex (MHC) 
molecules expressed on APCs. The major class of T cells express the TCR 
and differentiate into CD4 (helper) and CD8 (cytotoxic) T cell subsets (Bonilla 
and Oettgen 2010; Chaplin 2010). The T cell receptor (TCR) of naïve T cells, 
which is analogous to B cell Ag receptors, recognizes Ag presented by major 
histocompatibility complex (MHC) molecules expressed on APCs. MHC 
molecules are also known as the human leukocyte-associated (HLA) antigens 
and can be divided into class  and class  MHC molecules. Most conventional T 
cells express the  TCR but a small population, about 10% expresses the δ 
TCR. Unlike conventional T cells, δ T cells can directly recognise non-peptide 
antigens, such as microbial metabolites and phospholigands, and are enriched in 
mucosae and epithelial surfaces (Haas, Pereira et al. 1993; Sim, Olsson et al. 
1995).  
Class  MHC molecules bind endogenous 9-11 amino acid long peptide 
fragments synthesised from intracellular proteins encoded by the host genome or 
derived from infecting pathogens. The TCR of cytotoxic CD8 T cells interacts with 
peptides presented by class  MHC molecules, enhancing CD8 T cell activation. 
The 3 major types of human class  MHC molecules found on almost all 
nucleated cells are HLA-A, -B, and -C. In contrast, class  MHC molecules bind 
exogenous Ags ingested by endocytosis or phagocytosis and degraded to linear 
fragments by proteolysis within the APC. The TCR of CD4 T helper cells binds 
peptides presented by class  MHC molecules, enhancing CD4 T cell activation. 
The main types of cells expressing class  MHC molecules are DCs, B cells and 
macrophages. Stimulation of epithelial and capillary endothelial cells induces 
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class  MHC molecules allowing these cells to present peptides at inflammatory 
sites. Unlike constitutive expression of class  MHC molecules, class  MHC 
molecules can be induced by activation of innate immunity. The 3 major types of 
class  MHC molecules in humans are HLA-DR, HLA-DQ and HLA-DP. Cross-
presentation of Ag can also occur whereby exogenous Ag is taken up and 
presented by class  MHC molecules. This is important in overcoming some 
pathogens such as viruses that can suppress Ag presentation via the classical 
endogenous pathway (Rabson, Roitt et al. 2005; Bonilla and Oettgen 2010; 
Chaplin 2010).  
CD4 T cells generally support humoral responses and cell-mediated 
immune responses such as delayed type hypersensitivity responses, among 
others. Ag specific T-helper cells are activated after recognising Ag presented by 
APCs. They then secrete cytokines that cause Ag-specific B cells to clonally 
expand to produce high-affinity Abs. Cytotoxic CD8 T cells have direct effector 
functions and can kill infected cells and tumours in a contact dependant process. 
Target cells are killed either by apoptosis through CD8 T cell release of cytotoxic 
molecules, such as perforin, granzymes and granulysin, or via a Fas/FasL 
pathway (Bonilla and Oettgen 2010). 
Two signals are required for activation resulting in clonal expansion and 
differentiation of naïve T cells. Naïve T cells are first triggered when the TCR 
engages with peptide Ag presented by MHC molecules as described above. The 
second co-stimulatory signal is mediated via the binding of co-stimulatory 
molecules such as CD28 on the T cell and CD80 (B7.1) or CD86 (B7.2) on the 
APC. Naïve T cells that receive only the first signal produce only small amounts 
of IL-2, do not proliferate or differentiate and become anergic to Ag. Sustained 
proliferation and differentiation of activated T cells is driven by the cytokine IL-2 
produced by the activated T cells themselves (Bouneaud, Garcia et al. 2005). 
Naïve CD8 T cells are already predestined to become cytotoxic CD8 T cells. On 
the other hand naïve CD4 T cells activated by APC differentiate into T-helper 
type (Th)-1, Th2, Th17, Th9 or regulatory T cell (Treg) lineages depending on 
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activation of various transcription factors and also on cytokines in the 
microenvironment of the naïve cell (Fig. 1.1) (Janeway 2005; Rabson, Roitt et al. 
2005; Chaplin 2010). 
 
1.3.3 T cell effector subsets 
Innate immune cells can produce the cytokines IL-12 and IFN-  that bind cell 
surface receptors inducing pathways for the signal transducer and activator of 
transcription (STAT)-4 and T box expressed in T cells (T-bet). STAT4 and T-bet 
bind the IFN-  promoter driving naïve CD4 T cells to differentiate into Th1 cells. 
In mice STAT1 may also be an important mediator for TH1 differentiation as 
shown in a recent study (Ma, Huang et al. 2010). In general these cells support 
the cell-mediated immune response (Chaplin 2010). Th1 cells express mainly IL-
2, IFN-  and TNF-  and are important for protection against intracellular 
pathogens. The binding of IL-4 to cell-surface receptors activates STAT6, which 
initiates differentiation into Th2 cells expressing the transcription factor GATA3 
and the cytokines IL-4, IL-5, IL-9, IL-10 and IL-13. Th2 cells in general support 
the humoral response and are important in protection against extracellular 
pathogens (Romagnani 1997; Janeway 2005; Rabson, Roitt et al. 2005; Zhu, 
Yamane et al. 2006; Romagnani 2008; Chaplin 2010).  
In humans, the expression of the cytokines IL-1  and IL-6 or IL-1  or IL-23 
alone induces the initial commitment of naïve T cells to become Th17 cells. In 
contrast, murine Th17 cells are produced in response to the simultaneous 
production of IL-6 and TGF- . IL-23 expression is necessary for the maintenance 
of this cell lineage. Th17 cells express the transcription factor ROR t (retinoic 
acid receptor related orphan receptor t) and T-bet. Th17 cells mediate protection 
against extracellular bacteria and fungi by recruiting neutrophils. They express 
the cytokines IL-22 and mainly IL-17, which has protective effects against 
bacteria (Curtis and Way 2009; Romagnani, Maggi et al. 2009; Damsker, Hansen 
et al. 2010). However, Th17 cells may also be pathogenic and have been 
 10 
implicated in several human diseases. Over-expression of IL-17 is associated 
with a pro-inflammatory response and high levels of IL-17 have been found for 
example in patients with rheumatoid arthritis and Crohn’s disease (Kirkham, 
Lassere et al. 2006; Seiderer, Elben et al. 2008). Though unclear, Th17 cells also 
seem to play a significant role in patients with multiple sclerosis. In patients 
suffering from opticospinal multiple sclerosis, large amounts of IL-17 have been 
found in the cerebrospinal fluid (Ishizu, Osoegawa et al. 2005). In addition Th17 
cells have also been shown to be able to cross the blood brain barrier resulting in 
inflammation in the central nervous system parenchyma (Kebir, Kreymborg et al. 
2007). 
 
Figure 1.1. Naïve CD4 T cell differentiation into different T-cell effector subsets. Differentiation 
depends on the type of APC and cytokines in the microenvironment of the cell (arrows). The 
different T cell subsets express specific transcription factors (shown within the cell) and certain 
signature cytokines (Adapted from Bonilla and Oettegen 2010).  
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Another distinct lineage of T cells is that of regulatory T cells (Tregs). The 
precise signals that polarize naïve T cells to become Tregs are poorly 
understood, but IL-2 and TGF- cytokines aid in the maintenance of Tregs. 
These cells are able to suppress various immune functions (Fig. 1.2), maintaining 
immune homeostasis and preventing autoimmune and inflammatory diseases 
(Sojka, Huang et al. 2008). Tregs express the transcription factor FOXP3, the IL-
2 receptor  chain (CD25), and the immunosuppressive cytokines IL-10 and 
TGF- . Tregs may also play a role in suppressing vaccine induced protective 
immune responses (Bonilla and Oettgen 2010; Chaplin 2010). IL-4 and TGF-
can also induce Th9 cell differentiation, another recently described lineage of T 
cells that protect against helminth infections (Ma, Tangye et al. 2010). Th9 cells 
express large quantities of IL-9, a cytokine previously attributed to the Th2 cell 
lineage only (Soroosh and Doherty 2009). The specific transcription factor 
expressed by these cells is yet to be defined but this emphasises that these cells 
are different from Th2 cells that express GATA3 (Ma, Tangye et al. 2010).  
 
 
Figure 1.2. Regulatory T cells and the different immune functions they modulate (Sojka, Huang et 
al. 2008)  
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In short, the immune system is able to respond appropriately to 
extracellular and intracellular pathogens. The innate immune mechanisms 
provide the first line of defence against pathogens. The innate response is non-
specific and immediate and may stimulate the induction of the adaptive immune 
system to clear pathogens that evade innate immunity. The adaptive immune 
system is a specific form of acquired immunity induced by exposure to the 
pathogen (Janeway 2005; Calder 2007; Chaplin 2010). Table 1.1 summarizes 
some important differences between innate and adaptive immunity. Priming of 
naïve cells during the initial encounter with the pathogen results in clonal 
expansion of memory cells that can respond more effectively and rapidly upon 
secondary exposure to the pathogen. This is the hallmark of adaptive immunity 
that has been used as the basis of prophylactic vaccination strategies against 
pathogens (Janeway 2005). 
 
 




An estimated four million infants die annually from infections that are highly 
preventable by vaccination (Bonhoeffer, Siegrist et al. 2006).  Immunisation is 
one of the most important interventions in reducing morbidity and ultimately 
eradication of these diseases. The basic principles of immunisation are to 
stimulate the immune system with immunogenic Ags to induce memory cells, and 
upon exposure to the actual pathogen, memory cells will rapidly and effectively 
respond to provide protection. Individuals are vaccinated with harmless agents 
that can either be live attenuated (weakened) vaccine, a killed vaccine, an 
inactivated toxoid derived from the organism, or protein Ags derived from the 
organism (Baley and Leonard 2005; Rabson, Roitt et al. 2005). The World Health 
Organisation Extended Programme on Immunisation, (WHO EPI) started in 
1974, recommends that all children be vaccinated against the following important 
childhood infections for which vaccines exist: tuberculosis (TB), polio, diptheria, 
whooping cough, tetanus, Hepatits B, measles and Haemophilus influenzae type 
b (Hib) (Baley and Leonard 2005). Additional vaccines are added to the schedule 
depending on whether a particular vaccine preventable disease is endemic to 
that country. Since its inception millions of lives have been saved from vaccine 
preventable diseases.  
 
1.5 Tuberculosis epidemiology 
In 1882 Robert Koch identified Mycobacterium tuberculosis (Mtb) as the 
causative agent of human tuberculosis (TB). TB is one of the major causes of 
mortality globally despite availability of a vaccine and access to curative drug 
therapy. Data collected from 196 countries and territories and published by the 
World Health Organisation (WHO) gives a good indication of TB incidence and its 
trends. In 2008 there was an estimated 9.4 million incident cases of TB, up from 
9.1 million cases in 2005 and 11.1 million (range, 9.6-13.3 million) prevalent 
cases (WHO; Global Tuberculosis control: a short update to the 2009 report). TB 
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therefore remains a significant public health problem. The WHO Millennium goal 
is to reverse this incidence of TB disease globally with a target date set for the 
year 2015. However the African and European regions are behind track in 
reaching their set targets. For example, in 2005 the annual TB incidence in the 
Western Cape region of South Africa was the highest in the world, with an 
estimated 1037 cases per 100,000 population (Cowley, Govender et al. 2008).  
Based on the most recent data of all TB incidence cases, South Africa has the 
fifth highest rate in the world, behind India, China, Indonesia and Nigeria (WHO 
TB report 2009). The global distribution of new TB cases is shown in Fig. 1.3.  
 
 
Figure 1.3. Estimated rates of new TB cases worldwide in 2008. (Adapted from the WHO; Global 
Tuberculosis control: a short update to the 2009 report). 
 
The rise in incidence cases is largely in developing countries and has 
been attributed mainly to population growth and human immunodeficiency virus 
(HIV)-associated TB due to HIV co-infection (Corbett, Watt et al. 2003; Dye, Watt 
et al. 2005). Of all the new TB cases in 2008, 15% were HIV-positive and 78% of 
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these were found in developing countries in the African region (WHO; Global 
Tuberculosis control: a short update to the 2009 report). HIV-infected individuals 
have an estimated 15% annual risk of TB disease, compared to a 10% lifetime 
risk in HIV negative individuals (Whelan, Pathan et al. 2009). 
In addition, multidrug-resistant (MDR) TB is on the rise with an estimated 
50 million people infected (Dye, Espinal et al. 2002; Kaufmann 2002). MDR TB is 
resistant to the two first-line anti-TB drugs, isoniazid and rifampacin. The lengthy 
course of TB treatment leads to poor compliance and coupled with poor drug 
access in developing countries makes TB difficult to eradicate (Flynn 2004). 
Though rare, extensively drug-resistant (XDR) TB poses an even greater 
challenge to successful eradication of TB. XDR TB is resistant to almost every 
anti-TB drug, including the first-line and second line drugs, fluoroquinolones and 
at least one of the injectable anti-TB drugs (Gandhi, Moll et al. 2006). There is 
thus an urgent need to find ways to better control and eliminate TB. One of the 
best ways to control this epidemic is through prevention of TB disease by use of 
an effective vaccine. 
 
1.6 Pathogenesis and the immune response to TB 
An overview of the success of TB as a pathogen will help in understanding why it 
has become a global health problem. TB is contagious and is transmitted mainly 
via the respiratory route with humans as the natural host (Flynn 2004). Once in 
the lungs, Mtb replicates within alveolar ducts and within alveolar macrophages 
that transport the bacilli to draining lymph nodes where they present Ags to CD4 
T cells. Mtb also infects macrophages recruited to the site of infection from the 
bloodstream. These cells are not activated and thus cannot kill Mtb. Neutrophils 
are the main host cell infected with Mtb in TB patients (Eum, Kong et al. 2010), 
however Mtb can infect other cell types such as macrophages, DCs and 
epithelial cells (McDonough and Kress 1995; Abadie, Badell et al. 2005). Binding 
of Mtb to PRRs and to other receptors such as TLR2 and complement receptor 3 
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(CR3) facilitates uptake of Mtb into phagocytic cells (Schlesinger 1993; Ernst 
1998). 
 After Mtb infection the pathogen may be immediately cleared in a process 
that is yet to be defined in detail. However, approximately 5% of Mtb-infected 
people will fail to clear infection and develop primary tuberculosis within the first 
two years of infection, and another 5% develop TB later in life, whilst the 
remaining 90% control infection and establish an asymptomatic, latent infection. 
If not cleared, chronic Mtb infection leads to the formation of a granuloma. Mtb is 
able to survive within macrophages by preventing the phagosome-lysosome 
fusion pathway. A granuloma consists of fibroblasts, both CD4 and CD8 T cell 
lymphocytes and B cells surrounding macrophages, some infected with Mtb. The 
granuloma functions to contain the infection in localised sites preventing spread 
and allowing immune cells to act on infected cells. Caseous necrosis of the 
granuloma may occur forming cavities within the lung resulting in disseminated 
TB in other organs such as the liver and spleen, but more commonly Mtb 
remains in granulomas formed in these other organs.   
The metabolic state of Mtb within the granuloma is not well known but it 
was initially believed to be in a dormant non-replicative state. However, recent 
animal studies employing use of necropsies and imaging techniques such as 
high-resolution computed tomography (CT) and positron emission tomography 
(PET) suggest that Mtb may be metabolically active and replicating within the 
granuloma. Thus latency may represent a wide range of infection states. This 
latent phase can last for a lifetime and is characterised by a lack of clinical 
symptoms and adverse effects as Mtb has developed escape mechanisms and is 
able to survive within the granuloma. This presents a huge problem, as latently 
infected individuals are a reservoir of TB and may reactivate to develop TB 
disease. A reactivation of latent TB infection occurs in up to 10% of individuals, 
who fail to control infection. Reactivation may be as a result of a genetic 
predisposition, immunosuppression due to age or HIV infection, or malnutrition. 
This is mostly seen in adults and the disease presents itself as highly infectious 
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pulmonary TB. However, in immunocompromised individuals where granuloma 
formation may be compromised, Mtb infection is not well contained and can 
become a systemic disease spreading to other organs, as seen in HIV-infected 
individuals (Flynn 2004; North and Jung 2004; Barry, Boshoff et al. 2009). 
 
1.6.1 T cell responses to Mtb 
In most individuals an adaptive immune response is triggered to control infection. 
Mtb is an intracellular pathogen that usually resides in the vacuole of infected 
macrophages, and thus an effector T cell response rather than an antibody-
mediated response is required to clear infection. Following infection and uptake 
of Mtb by phagocytic cells such as macrophages and dendritic cells, IL-12 is 
released promoting a Th1 response. Infected macrophages can present Mtb Ags 
to T cells via the MHC Class II pathway resulting in a CD4 T cell response. CD4 
T cells produce various cytokines but mainly produce IFN-  in response to Mtb 
infection (Flynn 2004).  
As mentioned earlier, Mtb resides in intracellular vacuoles and thus Mtb 
Ags are mainly presented to CD4 T cells. However some studies have shown 
that Ag presentation may occur via the MHC class I pathway, thus activating CD8 
T cells. During the innate immune response APCs may cross-present Ag to CD8 
T cells (Schaible, Winau et al. 2003; Morel, Badell et al. 2008). CD8 T cells may 
be cytotoxic, targeting Mtb and clearing infection. Cells may be lysed by the 
action of perforin, which forms pores in the cell membrane of infected cells. 
Direct killing of Mtb is through release of granulysin, which gains access to 
intracellular Mtb through pores first created by perforin (Stenger, Hanson et al. 
1998). Cell death may lead to the killing of Mtb but may also release bacteria that 
can further infect activated macrophages (Flynn 2004). 
CD4 and CD8 T cells express IFN-  and TNF-  resulting in the activation 
of macrophages to become mycobacteriocidal (Flynn and Chan 2001). 
Individuals with mutations for IL-12p40 receptor, IFN-  receptor or genes for IFN-
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 production are more susceptible to Mtb, highlighting the importance of these 
cytokines (Lammas, De Heer et al. 2002). Studies have shown that even though 
IFN- is a requirement for a protective response, it is not a good immune 
correlate of protection against development of TB disease (Flynn 2004; Kagina, 
Abel et al. 2010). The importance of TNF-  is highlighted in patients who become 
more susceptible to severe forms of disseminated TB after undergoing anti-TNF-
 treatment for rheumatoid arthritis or Crohn’s disease (Keane, Gershon et al. 
2001). TNF-  also plays an important role in macrophage activation by acting 
synergistically with IFN- to maintain the granuloma (Cooper 2009).  
 
1.7 Diagnosis 
A pathological delayed-type hypersensitivity response is characteristic of an 
immune response to mycobacteria. This hypersentivity response can be initiated 
by the classic tuberculin skin test (TST/ Mantoux skin test). In this test, purified 
protein derivative (PPD) from Mtb is injected intradermally in the forearm. If the 
person responds an induration of the skin occurs and interpretations of results 
are usually done 48-72hrs after start of the test. Indurations of 10mm or more in 
diameter are considered as a positive test result indicative of mycobacterial 
infection (Gallant, Cobat et al. ; Huebner, Schein et al. 1993). This indicates prior 
exposure to mycobacteria but not necessarily disease. A subset of TB exposed 
people do not respond to the PPD test indicating that their innate immune system 
prevented infection but the mechanism by which this happens is largely unknown 
(Flynn 2004). However, this test is of little use in diagnosing active TB disease 
due to high rates of false positives (cross-reactive) and false negatives. Exposure 
to environmental mycobacteria and prior bacillus Calmette-Guérin (BCG) 
vaccination in individuals receiving the PPD test can lead to false positives due to 
cross-reactive immune responses to shared Ag in PPD and other mycobacteria. 
Active TB is thus commonly diagnosed by standard tests based on history of TB 
exposure, radiological tests and microbiological confirmation of Mtb in smear and 
 19 
culture tests from sputum or other disease sites (Chan, Heifets et al. 2000; 
Negrete-Esqueda and Vargas-Origel 2007). 
 
1.8 BCG vaccine 
The most widely used and the oldest of the vaccines to date is the BCG (Bacillus 
Calmette and Guérin) vaccine, the only licensed TB vaccine. In their search for a 
TB vaccine, Albert Calmette and Camille Guérin started working on the 
Mycobacterium Bovis strain from tuberculosis mastitis infected cows at a time 
when there was minimal understanding of the bacterium and the host immune 
system. This strain was serially passaged 231 times from 1906 to 1919 in 
medium containing glycerol, potato slices and beef bile. During this period the 
strain lost its virulence, first to calves and then to guinea pigs, and the first 
attenuated BCG vaccine was tested in humans in 1921 by Weil Halle (Fine 
2000). 
More than 4 billion people have received BCG since the start of its routine 
use in the 1960s. In the past the vaccine has been administered via different 
routes but the WHO currently recommends the intradermal route (Bricks 2004). 
The WHO also recommends that newborns in highly TB endemic countries be 
BCG vaccinated at birth unless they are symptomatically infected with human 
immunodeficiency virus (HIV) (Baley and Leonard 2005). BCG is also 
contradicted in persons with leukaemia, persons undergoing immunosuppressive 
therapy and pregnant mothers (Hussey, Hawkridge et al. 2007). The WHO does 
not recommend BCG vaccination after 1 year of age because protection is 
variable and uncertain. More than 4 billion people have received BCG since the 
start of its routine use in the 1960s. According to recent WHO-UNICEF 
estimates, in 2009 there was an estimated 88% global BCG immunisation 
coverage, whilst in South Africa this was estimated at 94% of the target 
population. Despite its extensive coverage TB still remains the leading cause of 
death from a curable infectious disease worldwide. 
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The original strain of BCG maintained by serial passage at the Pasteur 
Institute was distributed to manufacturers worldwide. Different laboratories 
maintained their own strains under different sub-culturing conditions. However 
the original BCG strain at the Pasteur institute was lost and as it was never 
cloned this has resulted in many different BCG strains from manufacturers 
around the world. Genotypic analyses show undoubtedly that these strains differ 
from each other and from the original BCG strain. Currently the major producers 
of BCG vaccines are Pasteur-Merieux-Connaught, the Danish Statens Serum 
institute, Evans Medava and the Japan BCG laboratory in Tokyo (Fine 2000; 
Hussey, Hawkridge et al. 2007). 
 
1.8.1 BCG vaccine efficacy 
The BCG vaccine protects infants against the more severe forms of TB such as 
TB meningitis and miliary TB, but protection in adults and infants against 
pulmonary TB is variable, resulting in the controversy surrounding this vaccine 
(Fine 1995; Hussey, Hawkridge et al. 2007). A meta-analysis of published reports 
has shown variable efficacy rates against pulmonary TB ranging from 0-80% 
(Trunz, Fine et al. 2006; Hussey, Hawkridge et al. 2007; Negrete-Esqueda and 
Vargas-Origel 2007). Years later a BCG induced memory response can be 
detected in vaccinated individuals. However, the response wanes with time and 
some studies have indicated that an immune response wanes after 20 years but 
may persist for as long as 60 years (al-Kassimi, al-Hajjaj et al. 1995; Aronson, 
Santosham et al. 2004).  
Some possible reasons for variable efficacy rates are environmental 
mycobacteria, helminth infections and host genetics (Hussey, Hawkridge et al. 
2007). These may modulate the immune response to BCG and interfere with 
BCG-induced protection. Exposure to other environmental mycobacteria post-
BCG vaccination may lead to cross-reactive immunity that blocks BCG-induced 
protective immune responses (Brandt, Feino Cunha et al. 2002; Flaherty, 
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Vesosky et al. 2006). Environmental mycobacteria are thought to also mask BCG 
induced immunity. In masking, antimycobacterial immunity induced by 
environmental mycobacteria cannot be improved upon by subsequent 
vaccinations (Buddle, Wards et al. 2002). This may be the underlying reason why 
BCG is less effective in tropical regions where environmental mycobacteria are 
generally more abundant (Fine 2000). Failure of BCG to provide adequate 
protection in environments where chronic infections are prevalent has led to the 
hypothesis that chronic helminth infections may affect BCG efficacy (Hori, 
Watanabe et al. 1993). Helminth infection may skew the immune system towards 
a Th2 type response (Kullberg, Pearce et al. 1992) instead of a Th1 response 
required for protection against Mtb. The environment alone cannot explain the 
variable efficacy of BCG. Host genetics pay a role as BCG induced protection 
varies between different populations (Colditz, Brewer et al. 1994; Fine, Carneiro 
et al. 1999).  
Thus much work is underway to understand BCG, TB and to produce new 
TB vaccines. Although knowledge in this field is on the rise little is actually known 
about the host factors affecting BCG induced immunity to prevent TB. To 
advance in the development of a more efficacious vaccine against TB, it is 
important to characterise host factors that may modulate the immune response 
induced by BCG vaccination at birth, as infants are potentially the target 
population for new improved vaccines against TB.  
Other potentially important factors that may influence BCG induced 
immunity are birth weight, gestational age (GA) and size for GA at time of 
vaccination. Firstly, a better understanding of these host factors and lessons that 
can be learnt from other early life responses and vaccines is needed before 
investigating them in the context of BCG vaccination. 
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1.9 Infant birth weight and size for gestational age 
The term low birth weight (LBW) refers to infants born weighing less than 2,500g. 
Infants weighing between 1,000 and 1,499g are classified as very LBW (VLBW) 
and extremely LBW if they weigh between 500 and 999g. Premature or pre-term 
(PT) LBW infants are infants born ≤37 weeks gestation, and term LBW infants 
are born between 38 and 41 weeks of gestation. LBW infants born after 41 
weeks are classified as post term. Size for gestational age is based on foetal 
body weight percentiles and standard growth curves of infants. Small for 
gestational age (SGA) infants have a birth weight less than the lower 10th 
percentile of the standard growth curves. Appropriate for gestational age (AGA) 
infants have birth weights between the 10th and 90th percentile, and large for 
gestational age (LGA) infants have a birth weight above the 90th percentile. Intra-
uterine growth restriction (IUGR) is commonly a result of poor maternal nutrition 
but can be any process limiting intra-uterine growth resulting in LBW. LBW and 
IUGR do not always represent the same situation, as some SGA infants are 
healthy whilst some AGA infants show signs of IUGR (Valero De Bernabe, 
Soriano et al. 2004; Raqib, Alam et al. 2007). 
 LBW is an important public health indicator. There are increased rates of 
morbidity and mortality in LBW infants compared to NBW infants. Consequences 
of prematurity, LBW and IUGR on development can also extend to later years in 
life. Depending on the specific cause, these infants may have increased 
rehospitalisation rates, lower intellectual quotients (IQ), impaired neurological 
functions and may develop hypertension, diabetes and coronary heart disease as 
adults (Ballow, Cates et al. 1986; Valero De Bernabe, Soriano et al. 2004). The 
reasons for LBW are complex but the primary cause is premature birth. The risk 
factors that may contribute to LBW are extensively reviewed by Bernabe et al 
(Valero De Bernabe, Soriano et al. 2004). Table 1.2 below summarises some of 
these risk factors and their outcomes.  
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Table 1.2. Risk factors and outcomes pertaining to low birth weight (Valero De Bernabe, Soriano 
et al. 2004). 
 
2.0 Birth weight, maturity and the neonatal immune response 
The innate and adaptive immunity of neonates is fundamentally the same as that 
of adults, as described in the previous sections. However, some functional 
differences in the human neonatal immune system have been observed. These 
differences have resulted in the classification of the neonatal immune system as 
immature, compared to adults.  
As discussed earlier, APCs induce the adaptive immune response. 
Neonatal APCs are functional but express low levels of CD80 and CD86, co-
stimulatory molecules required for the clonal expansion and differentiation of 
naïve T cells. Thus neonatal DCs have a reduced capacity to promote Th1 
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responses (Goriely, Vincart et al. 2001; Velilla, Rugeles et al. 2006). Even though 
at the mRNA level TLR expression in adults and neonates is similar, impairment 
of TLR1, TLR2, TLR4 and TLR6 immune function have been described. For 
example, expression of the proinflammatory cytokines TNF-  and IL-12 in 
response to TLR4 ligands, such as bacterial lipopolysaccharide (LPS), is low in 
neonates compared to adults. TLR4 protein expression has been found to be 
lower in PT infants compared to term infants. Furthermore, neonatal monocytes 
exhibit a lower capacity to phagocytose E.coli compared to adult monocytes; this 
impairment is even more pronounced in PT infants born <30 weeks gestation 
(Velilla, Rugeles et al. 2006). PT LBW infants are particularly prone to 
pneumococcal infections, whilst LBW infants are at a greater risk of pertussis 
infections (Bonhoeffer, Siegrist et al. 2006). Taken together, these findings may 
explain the increased susceptibility of PT infants to infections that are otherwise 
not as harmful in full term infants and adults (Velilla, Rugeles et al. 2006). 
Expression of immunosuppressive cytokines by Tregs helps to maintain 
immune homeostasis. Tregs are found in high numbers within the uterine lining 
and play an important role in maintaining pregnancy by suppressing inflammatory 
responses. Tregs also develop spontaneously in the human foetus and in 
newborn infants. Unlike adult cells, Tregs found in cord blood have a naïve 
phenotype with high levels of CD45RA expression. At birth the frequency of 
Tregs is higher in PT infants compared to full term infants. This suggests that 
infant Tregs may be detrimental for Ag specific immune responses, and 
particularly more so in PT infants. Expression of trophoblast derived IL-10 is 
another immunoregulatory mechanism to maintain pregnancy. IL-10 inhibits Th1 
responses that would otherwise harm the foetus. A characteristic of this 
immunoregulation is the impaired CD4 T cell expression of IFN-  and IL-2 and 
responses that are skewed towards a Th2 response in neonates compared to 
adults. Decreased expression of IFN-  is due to hypermethylation of certain sites 
of the promoter region of the IFN-  gene (Melvin, McGurn et al. 1995; Velilla, 
Rugeles et al. 2006).  
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A study by Gasparoni et al evaluating immune development showed not 
only that neonatal responses are impaired but that there is also a gradual 
maturation from birth to adulthood. In this study, IL-2, IL-4, IL-10 and IFN-  
expression was compared among very pre-term infants (20-29 weeks GA), PT 
infants (30-37 weeks GA), term infants (38-42 weeks GA), children (3-10 years 
old) and adults. The percentage of naïve T cells expressing CD45RA was higher 
in newborns compared to all other groups.  IL-2, IL-10 and IFN-  expression by T 
cells was found to be negatively associated with GA. The activity of NK cells was 
impaired in neonates and was positively associated with GA (Gasparoni, Ciardelli 
et al. 2003). 
 There is also evidence that gradual maturation of the neonatal immune 
system is directly correlated with vaccine-induced protection. Antibodies directed 
against most bacterial polysaccharides (PSs) are only produced in infants 2 
years or older, leaving younger infants susceptible to invasive disease caused by 
organisms such as Haemophilus influenza type B (Hib). Vaccines given in the 
first 6 months of life, with the exception of BCG, require several doses to achieve 
protective responses. A single dose of either oral polio virus (OPV) or diphtheria-
tetanus toxoid at birth induces very low levels of neutralising Ab (Siegrist 2001).  
A gradual increase in responses with age has been reported, for example the Hib 
conjugate vaccine is most immunogenic when administered as a single dose at 
15-23 months of age, compared to 3 doses in the first 6 months of life. In 
addition, Hib induces higher serum Ab levels at 4-6 months than at 2-3 months of 
age (Siegrist 2001). A similar gradual increase has also been observed with 
measles vaccination, with lower Ab responses at 6 months compared to 9, 12 
and 15 months of age (Gans, Arvin et al. 1998; Bonhoeffer, Siegrist et al. 2006).  
The following vaccines are all recommended by the American Academy of 
Pediatrics to be administered at the full dosage to healthy PT LBW infants and to 
term NBW infants at 2 months of age: Hib conjugate; diphtheria, tetanus, 
acellular pertussis (DTap); inactivated polio virus (IPV) and Pneumococcal (Pn) 
conjugate. These vaccines induce significantly higher neutralising Abs in infants 
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when administered at this age than at birth (Baley and Leonard 2005). The 
hepatitis B vaccine has a different regime for PT LBW infants compared to term 
infants. Birth weight affects the immunogenicity of this vaccine, as infants 
weighing less than 2,000g are less likely to mount sufficiently high levels of 
neutralising Ab. It is recommended that the hepatitis B vaccine be delayed if the 
mother is hepatitis B surface Ag (HBsAg) negative and the infant weighs less 
than 2,000g. These infants should only be vaccinated once they reach a birth 
weight of 2,000g, or when they are 2 months of age (Baley and Leonard 2005). 
LBW as a result of nutritional deficiencies may also affect the immune 
system as growth of lymphoid organs is sensitive to nutrition and is positively 
associated with age (Langley-Evans and Carrington 2006). Anti-typhoid Ab 
responses in a group of Filipino adolescents was positively associated with birth 
weight (McDade, Beck et al. 2001). Studies in the Gambia have shown that birth 
in the rainy hungry season (July-December) resulting in LBW, compared to birth 
in the harvest season (January-June), is associated with increased mortality from 
infectious disease later in life (Moore, Cole et al. 1997; Moore, Cole et al. 1999). 
The hungry season is marked by increased seasonal infections and shortage of 
food when food supplies from the previous harvest season run out (Moore, 
Fulford et al. 2004). These infants were found to have lower expression of 
CD154, a ligand that enhances the killing capacity of human macrophages and 
monocytes and which may play a role in protection against Mtb (Miles, van der 
Sande et al. 2008). 
Lastly, the neonate humoral response is also relatively immature at birth 
compared to adults. In the first year of life Ab responses are weak and short 
lived. An infant’s immune system largely depends on passively transferred 
maternal antibodies (Abs) for protection. Maternal immunoglobulin (Ig)-G Abs are 
mostly transferred across the placenta during the third trimester of pregnancy. 
During breast feeding IgG and IgA Abs are transferred to the neonate. Maternal 
Abs confer passive immunity for up to 18 months against bacterial and viral 
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pathogens that the mother was immune to prior to giving birth or to breastfeeding 
(Baley and Leonard 2005; Janeway 2005). 
The evidence presented here indicates that some neonatal immune 
responses are immature, or different, compared to adult responses. There is also 
evidence of a gradual maturation of the immune system in neonates to adults. 
Functional impairment of the neonatal immune system may explain the variable 
Th1 responses to vaccines and increased susceptibility to intracellular pathogens 
usually exhibited by neonates.  
 
3.0 Current study: Aims and objectives 
Neonatal immunological immaturities may be more pronounced in the least 
mature group of PT LBW infants. Evidence of neonatal immune immaturity 
provides rationale for performing a study assessing the effects of birth weight and 
gestational age on BCG-induced cellular immunity. 
Aim 1: 
To determine the effect of birth weight and gestational age on the phenotype and 
magnitude of the BCG induced T cell response  
Hypothesis: BCG-vaccinated PT and LBW infants would have a lower frequency 
of BCG-specific T cells, compared to term NBW infants. 
Aim 2: 
To determine the effect of birth weight and gestational age on the proliferative 
potential of BCG-specific T cells following BCG vaccination  
Hypothesis: BCG vaccination at birth induces antigen-specific T cells with a 
greater proliferative and cytokine producing capacity in NBW infants compared 


























An adaptive immune response mediated by lymphocytes is critical in the 
clearance of various pathogens. Many novel vaccines aim to induce an antigen-
specific T cell response, and measuring this cellular immune response is 
important in assessing vaccine immunogenicity and efficacy. Several methods, 
many of them based on flow cytometry, can be used to study the frequency and 
phenotype of antigen-specific T cells. 
Antigen-specific T cells may be indirectly detected by measuring secreted 
cytokines at the population level, by an enzyme-linked immunosorbent assay 
(ELISA). An enzyme-linked Immunospot (ELISpot) assay is more sensitive and 
can be used to detect secreted cytokines at the single cell level. T cell effector 
functions, such as cytotoxicity, may be detected in vitro by a chromium release 
assay. Target cells labelled with 51Cr and pulsed with antigen are incubated with 
cytotoxic T-lymphocytes (CTLs). CTLs specifically kill target cells and thus cell-
mediated cytotoxicity can be measured by the release of radioactive 51Cr into the 
culture supernatant (Kern, LiPira et al. 2005).  
Alternatively, T cells may be directly analysed by staining them with 
fluorescently labelled major histocompatibility complex (MHC) tetramers. These 
specific MHC tetramers have a high avidity to target T cell receptors, ensuring a 
high signal when analysed by flow cytometry (Thiel, Scheffold et al. 2004). 
Antigen-specific T cells may also be directly detected by their in vitro ability to 
proliferate, or synthesise deoxyribonucleic acid (DNA) following activation as 
described later (2.1.2).  
The advent of intracellular cytokine staining (ICS) to detect cytokine 
expression at the single cell level (Suni, Picker et al. 1998) has greatly advanced 
the field of cellular immunology. T cells are stimulated with antigen to induce 
cytokine production, and then fixed, permeabilised and stained with fluorescently-
conjugated monoclonal antibodies (Abs) (Kern, LiPira et al. 2005). ICS assays 
were first used to detect responses in peripheral blood mononuclear cell (PBMC) 
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cultures and later modified for use in whole blood cultures in field studies (Suni, 
Picker et al. 1998). This modified whole blood intracellular cytokine (WB-ICC) 
assay is described in more detail below (2.1.1).  
 
2.1.1 Whole blood intracellular cytokine (WB-ICC) assay and flow cytometry 
The whole blood intracellular cytokine (WB-ICC) assay is one method that can be 
used to measure the frequency of cytokine-producing, antigen-specific T cells in 
adults and infants (Fuhrmann, Streitz et al. 2008). The advantages outlined 
below made this the main assay of choice in this study to measure BCG-specific 
T cell responses.  
The WB-ICC assay has been optimised and shown to be a sensitive and 
specific assay with reproducible results (Hanekom, Hughes et al. 2004). This 
assay does not require carbon dioxide and requires only a small volume of blood, 
which is immediately stimulated with antigen after venipuncture (Hanekom 2005). 
It has been optimised to cater for studies where blood collection is done offsite, 
typically at a rural clinic far from the laboratory where the immunological assays 
are done. Blood collected at the rural clinic is incubated with antigen and 
transported in a portable incubator to the laboratory where incubation is 
continued in a programmable waterbath and the assay completed with the 
fixation and cryopreservation of white cells (Hanekom, Hughes et al. 2004; Thiel, 
Scheffold et al. 2004). 
To initiate the short-term stimulation with antigen, blood is collected in 
sodium heparanised syringes and added to polypropylene tubes containing an 
antigen of choice in the presence of co-stimulatory Abs such as anti-CD28 and 
anti-CD49d. Co-stimulants are added to enhance the specific stimulatory 
capacity of effector T cells and maximize the detection of cells producing 
cytokines such as IFN . Whole blood may be incubated in a short term assay 
(<20 hrs), or in longer term assays (up to 7 days) after first diluting it in RPMI 
media. A Golgi transport inhibitor, such as Brefeldin A or monensin, is added 
during the last several hours of incubation to block secretion of cytokines by 
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preventing protein transport from the endoplasmic reticulum (ER) to the Golgi 
complex. After incubation, cells are harvested, red blood cells lysed, the white 
cells fixed and cells or ribonucleic acid (RNA) cryopreserved for later analysis. 
Plasma from the incubated whole blood may also be collected prior to addition of 
Brefeldin A and stored for later analysis of soluble factors secreted during the 
initial stimulation period.  
After antigen stimulation of whole blood, intracellular cytokine staining of 
lymphocyte populations may be performed. Most of the detectable intracellular 
cytokines are a result of addition of a protein transport inhibitor that blocks 
cytokine secretion and allows for detection of cytokines within the cytoplasm of 
cells. Thus stimulated, fixed cells that have been cryopreserved are thawed, and 
permeabilised to allow detection of intracellular cytokines. Cytokines of interest 
found within the permeabilised cells are detected by staining with fluorescently-
conjugated monoclonal Abs (Soares, Scriba et al. 2008).  
Lastly, stained cells are analysed by flow cytometry (Janeway 2005), a 
technique to detect fluorescently labelled particles as they flow in a fluid system 
through a laser beam. Particles such as fluorescently labelled cells are forced 
through a nozzle in a single fluid stream of droplets that flows perpendicular to 
the laser beam. When they intercept the laser beam they will deflect and scatter 
the incident laser light whilst the fluorochrome is excited, thus emitting 
fluorescence. The physical properties of each particle determine the extent of 
light scatter. Light scattered in the forward direction, forward scatter (FSC) gives 
information on the size and surface area of the particle. Light scattered at an 
angle of 90  to the incidence laser beam is called side scatter (SSC) and gives 
information on the granularity of the particle. Scattered light and fluorescence 
signals given off by the fluorescently stained particles are detected by sensitive 
photomultiplier tubes (PMTs). Finally, signals are converted to information that 
can be analysed by a computer (Janeway 2005). Multiparameter flow cytometry 
allows measurement of several fluorochromes simultaneously on a single cell 
basis. In this study, the use of a three-laser LSR II flow cytometer enabled the 
acquisition and detection of cells co-stained with different fluorochrome-
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conjugated monoclonal Abs (Fuhrmann, Streitz et al. 2008).  After acquisition, 
data analysis enables the delineation of different cell types, cell subsets and 
intracellular cytokines expressed.  
Several factors must first be considered when developing an optimum 
polychromatic Ab panel for flow cytometry so that results are reliable and 
reproducible. Firstly, the fluorochrome-Ab combination should be carefully 
chosen based on expression levels of the target protein to allow optimum 
detection. Proteins of interest that are expressed at low levels should ideally be 
labeled with the brightest fluorochromes in that Ab panel. The amount of Ab 
should be titrated to determine the Ab volume that gives the best signal to noise 
ratio. Unwanted spectral overlap of one fluorochrome into the detector of another 
fluorochrome is another problem to consider as it can complicate data analysis. 
Such fluorescence spill-over can be reduced or eliminated by titrating antibodies 
and carefully choosing fluorochromes with different excitation spectra.  Spectral 
overlap can be assessed by investigating the frequency of the labeled protein 
with and without each single fluorochrome in that Ab panel in “fluorescence 
minus one” experiments. In addition with the use of appropriate compensation 
controls and analysis software, spectral overlap may be compensated for using 
flow cytometry analysis software such as FlowJo. The number of fluorochromes 
in a panel is also important, as spectral overlap and measurement errors worsen 
as the number of fluorochromes increase, even when the panel is properly 
compensated. Testing the desired Ab panel with different permutations of 
fluorochrome-Ab combinations can be time consuming and expensive. A 
common method of optimising a polychromatic Ab panel is to first optimise a 
smaller subset of the desired panel and then to systematically add and optimise 
additional fluorochrome-Abs until the panel is complete (Baumgarth and 




2.1.2 Lymphocyte proliferation assay and flow cytometry 
Another method to measure adaptive immune responses in vitro is by the ability 
of lymphocytes to proliferate and expand in response to antigen stimulation. 
Lymphocytes can be isolated from peripheral blood by density gradient 
centrifugation of anticoagulated blood over a layer of Ficoll. The resulting cell 
population, consisting of mainly lymphocytes and monocytes, are called 
peripheral blood mononuclear cells (PBMCs) (Gulati 2009). 
 PBMCs, either cryopreserved or freshly isolated, can be incubated with 
specific antigens in either short or long-term assays. Proliferation of antigen 
specific cells is usually detected following 6-7 days of antigen stimulation in vitro, 
and may be measured by the uptake of radioactive nucleotides, such as tritiated 
thymidine (3H), or nucleotide analogues, such as bromodeoxyuridine (BrdU), into 
the DNA of replicating cells (Weston and Parish 1990; Fulcher and Wong 1999). 
The amount of these incorporated DNA precursors is proportional to the amount 
of proliferation.  
Another method to monitor lymphocyte proliferation is based on the 
combined use of cell trace dyes and flow cytometry. In this assay system, PBMC 
are stained with a cell trace dye such as carboxyfluorescein diacetate 
succinimidyl ester (CFDA-SE) or Oregon Green (OG: 2', 7’-difluorofluorescein), 
and labelled cells incubated with antigen. Cell trace dyes bind cellular proteins 
and when these stained cells proliferate, the cell trace dye is partitioned equally 
between daughter cells and the fluorescence intensity decreases by 50% with 
each cell division. The advantage of using cell trace dyes is that the number of 
cell divisions and the precursor cell frequency of antigen-specific cells can be 
quantified by flow cytometry. Another advantage is that cells may be co-stained 
with phenotypic markers and intracellular cytokines followed by multiparameter 
flow cytometric analysis, thereby allowing detailed characterization of populations 
of antigen-specific T cells with proliferative capacity (Lyons and Parish 1994; 
Lyons 2000; Wallace, Tario et al. 2008). 
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Intracellular detection of the human nuclear protein Ki-67 presents another 
flow cytometry-based method of assessing antigen-specific proliferation 
(Shedlock, Talbott et al. 2010). Most circulating lymphocytes isolated from 
peripheral blood are in the resting phase until stimulated with antigen where upon 
they actively divide (Gulati 2009). Ki67 can be used as a marker of proliferation in 
vitro as it is expressed in the nuclei of actively dividing cells during the G1, G2, S 
and mitosis phase, but not in resting cells (G0) (Jeurink, Vissers et al. 2008). 
Proliferating cells can then be detected by intracellular staining of Ki-67 using 
fluorescently-conjugated monoclonal Abs. 
The cytokine production capacity of antigen-specific proliferating T cells 
can be further assessed following restimulation of cells with specific antigens or 
mitogens, such as phorbol 12-myristate 13-acetate (PMA) and ionomycin, for the 
final 4-6 hours of the incubation period. Cells may also be stained with viability 
dyes enabling the differentiation of live cells from dead cells by flow cytometry. 
Furthermore, cell culture supernatants can be harvested at the end of the 6-day 
incubation period and stored for later analysis of soluble molecules that have 
been secreted and accumulate in the media over the culture period. 
In summary, various ways to measure antigen-specific responses have 
been developed, however the resources available for the current study have 
influenced the choice of assays in our experimental system. South Africa is a 
developing country and participant recruitment was done at an established 
clinical site in a rural area. The WB-ICC assay was chosen as the most practical 
assay in our setting as outlined before, and the use of Ki67 as a sensitive marker 
of antigen-specific T cell proliferation was explored.   
 35 
2.2 Materials and methods 
 
2.2.1 Study participants 
Healthy infants not requiring hospitalization, vaccinated intradermally or 
percutaneously within 24h of birth with Japanese BCG vaccine (strain 172, 
Japanese BCG laboratory) were recruited from Worcester in the Western Cape 
region of South Africa. Participants were selected from a larger randomised 
control trial (RCT; n=11,670) investigating the incidence of TB over 2 years in 
infants vaccinated at birth intradermally or percutaneously with Japanese BCG 
(Hawkridge, Hatherill et al. 2008). For this study, enrolled infants were stratified 
by birth weight into one of the following groups based on World Health 
Organisation (WHO) definitions: (i) low birth weight (< 2,500g) and (ii) normal 
birth weight (≥ 2,500g). The gestational age, as calculated from the mothers last 
menstrual period, was recorded for all infants. Maturity was noted and standard 
definitions used to classify infants as pre-term (PT) if born at ≤ 37 weeks 
gestation, and as term if born between 38 and 41 weeks gestation.  Size for 
gestational age was based on fetal body weight percentiles and standard growth 
charts of infants aged 28-43 weeks (Naeye and Dixon 1978). Infants with a birth 
weight below the 10th percentile were classified as small for gestational age 
(SGA). Appropriate for gestational age (AGA) infants had birth weights between 
the 10th and 90th percentile. Large for gestational age (LGA) infants had a birth 
weight above the 90th percentile. Infants presenting with any chronic or acute 
illness at 10 weeks of age were excluded. At 10 weeks of age, at a routine 
childhood immunization visit, approximately 10mls of heparinised blood was 
collected by a dedicated qualified nurse by standard venipuncture technique. 
Two millilitres of blood were immediately processed for use in a whole blood 
intracellular cytokine (WB-ICC) assay described later. Approximately 8ml of 
blood was collected in Vacutainer Cell Preparation Tubes (CPT, Becton 
Dickinson). Written, informed consent was obtained from the parents or legal 
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guardian. The study protocol was approved by the Human Research Ethics 
Committee of the University of Cape Town. 
2.2.2 Peripheral blood mononuclear cell (PBMC) collection 
Blood was collected in Vacutainer Cell Preparation Tubes (CPT, Becton 
Dickinson) and peripheral blood mononuclear cells (PBMCs) isolated by density 
gradient centrifugation over a layer of Ficoll (HISTOPAQUE®-1077: Sigma-
Aldrich). Multiple aliquots of PBMCs at 10 million per cryovial were cryopreserved 
in 10% dimethylsulfoxide (DMSO), 40% fetal calf serum (FCS) and 50% RPMI, 
and stored in liquid nitrogen until use. 
 
2.2.3 Antigens  
Viable Mycobacterium bovis Bacillus Calmette-Guérin [(BCG), Danish strain 
1331, Statens Serum Institute)] was incubated with: (i) heparinised whole blood 
at a final concentration of 1.6 x 106 CFU/ml of blood, or (ii) 2 x 105 PBMCs at a 
final concentration of 2 x 105 CFU/ml. Staphylococcal enteretoxin B (SEB; 
Sigma-Aldrich), included as a positive control, was incubated with: (i) heparinised 
whole blood and (ii) 2 x 105 PBMCs at a final concentration of 10µg/ml and 
0.05 g/ml, respectively. On the 6th day of the proliferation assay, PBMCs were 
restimulated with 50ng/ml of phorbol 12-myristate 13-acetate (PMA; Sigma-
Aldrich) and 250ng/ml of ionomycin (I; Sigma-Aldrich). 
 
2.2.4 Whole blood intracellular cytokine (WB-ICC) assay 
The co-stimulatory Abs anti-CD28 and anti-CD49d (0.5 g/ml each, BD 
Biosciences) were included in all conditions of the WB-ICC assay. One ml of 
peripheral blood was incubated with BCG, whilst 500µl blood incubated with SEB 
served as a positive control. As a negative control, 500µl blood was incubated 
with costimulatory Abs alone. The WB-ICC assay was performed as described 
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previously (Hanekom, Hughes et al. 2004). Briefly, blood was incubated with 
antigens at 37 C in a portable incubator and transferred 100km by car from 
Worcester to the South African Tuberculosis Vaccine Initiative (SATVI) research 
laboratory, where the incubation was continued in a 37 C programmable 
waterbath.  After 7h, Brefeldin A (10µg/ml; Sigma-Aldrich) was added and the 
incubation continued for an additional 5h. Cells were harvested after a total 
incubation time of 12h. EDTA was added (2mM, Sigma Aldrich), red blood cells 
lysed and white blood cells fixed by diluting the blood 1:10 with FACS Lysing 
solution (BD Biosciences). After a 10min incubation in FACS Lysing solution at 
room temperature (RT), the fixed white blood cells were centrifuged at 1400rpm 
for 7min at RT. Cells were resuspended in cryo-solution by first resuspending 
them in 250µl RPMI followed by addition of 250µl 20% DMSO (E Merck) in FCS. 
The fixed white blood cells were cryopreserved and stored in liquid nitrogen until 
use. 
 
2.2.5 Six day PBMC proliferation assay 
Cryovials containing infant PBMCs stored in liquid nitrogen were thawed quickly 
in a 37 C waterbath. The contents of each vial were transferred dropwise into a 
15ml conical tube containing 10ml 12.5% heat inactivated human AB serum in 
RPMI (complete medium) and 2.5 g/ml DNase (Sigma-Aldrich). Tubes were 
centrifuged at 400g for 10min, supernatant decanted and cells resuspended 
gently with 1ml of complete medium. After resuspension, cells were counted with 
a Coulter machine (Beckman Coulter Ac.T diffTM Analyser) and the concentration 
adjusted to 1 x 106/ml with complete media containing 2mM L-glutamine (Bio 
Whittaker). Using a Gilson p200 pipette, 2 x 105 cells per well were transferred to 
wells of a 96-well, round-bottomed plate (NUNC). Cells were plated in triplicate 
wells for each stimulation condition.  
Cells were rested overnight at 37ºC, 5% CO2 in a humidified incubator 
before addition of antigen. After resting, 2 x 105 cells per well were either left 
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unstimulated (negative control) or stimulated with BCG and SEB as described 
earlier (2.2.3). Cells were then incubated for 6 days in a 96-well, round-bottomed 
plate (NUNC) at 37ºC, 5% CO2 in a humidified incubator.  
A dye dilution method where cells were labeled with Oregon Green (OG: 
2', 7’-difluorofluorescein; Molecular Probes) was also used in some experiments 
to investigate antigen-specific proliferation. For the OG proliferation assays, 
cryopreserved PBMCs were thawed and washed as outlined above, followed by 
another wash in PBS, supernatant decanted and cells resuspended gently in 1ml 
PBS. Cells were counted with a Coulter machine (Beckman Coulter Ac.T diffTM 
Analyser) and adjusted to no more than 1 x 107/ml viable cells in PBS. Prior to 
resting, an equal volume of 10 g/ml working solution of OG in PBS was added to 
each 15ml conical tube containing the adjusted number of resuspended viable 
cells. Tubes were mixed gently, left to stand at RT for 3min, mixed vigorously by 
vortexing for 10sec, followed by 4min incubation at RT. An equal volume of PBS 
was added followed by gentle mixing and 4min incubation at RT. Each tube was 
filled to the top with PBS and centrifuged at 400g for 5min. The supernatant was 
decanted and cells resuspended in 1ml of complete medium containing 2mM L-
glutamine (Bio Whittaker). Cells were rested overnight in a 96-well plate in a 
37ºC, 5% CO2 humidified incubator, antigen added the following day and cells 
incubated for 6 days as described above.  
On the 6th day of all proliferation assays, cells were restimulated with PMA 
and Ionomycin (PMA/I); Brefeldin A (10 g/ml) was added and cells incubated for 
5h at 37ºC, 5% CO2 in a humidified incubator. Negative controls consisted of 
unstimulated PBMCs, and unstimulated PBMCs from day 1 of the assay 
restimulated on day 6 with PMA/I (PMA/I negative control). After 5h, 2mM EDTA 
was added and cells incubated for 15min at RT. Cells were centrifuged at 
2200rpm and washed in PBS, centrifuged, and supernatant removed. Cells were 
stained for 30min at RT with violet viability dye (ViViD; LIVE/DEAD Fixable Violet 
Dead Cell Stain Kit, Molecular Probes, Invitrogen). After staining, cells were 
washed in PBS and centrifuged at 2200rpm, supernatant removed and cells fixed 
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by the addition of FACS Lysing solution for 10min at RT. Stimulated, fixed cells 
were cryopreserved and stored in 96-well plates (NUNC) at -80ºC until use. 
 
 
2.2.6 Antibodies and staining of cryopreserved whole blood and PBMCs 
Fixed, stimulated cells from the WB-ICC assay were placed in a 37 C waterbath 
for quick thawing. Once thawed, samples were transferred by pipette to Falcon 
2054 FACS tubes containing 3mls of PBS. FACS tubes were centrifuged at 
2000rpm for 5min, supernatant decanted and cells resuspended gently in 1ml of 
1X Perm/Wash buffer (BD Biosciences). Cells were left at RT in Perm/Wash 
buffer for 10min to permeabilise them. After 10min incubation, FACS tubes were 
centrifuged at 2000rpm for 5min at RT. Supernatant was decanted and cells 
stained at 4 C for 1h in the dark with the following fluorochrome-conjugated 
monoclonal Abs: anti-CD3 Pacific Blue (UCHT1), anti-CD4 Qdot 605 (S3.5), anti-
CD8 Cy5.5-PerCP (SK1), anti-IL2 FITC (5344.111), anti-IFN  Alexa Fluor 700 
(B27), anti-TNF  Cy7-PE (MAb11) and anti-IL17 Alexa Fluor 647 
(eBio64CAP17).  
For analysis of 6-day proliferation assay samples, frozen NUNC plates 
containing fixed stimulated cells were thawed at RT and centrifuged at 2300rpm. 
Supernatant was removed, cells resuspended in Perm/Wash buffer (BD 
Biosciences) and incubated at RT for 10min to permeabilise cells. Thereafter 
cells were transferred to FACS tubes and centrifuged at 2000rpm for 5min and 
supernatant decanted. Cells were stained at 4 C for 1h in the dark with the 
following fluorochrome-conjugated monoclonal Abs: anti-CD3 FITC (Leu-1), anti-
CD8 Cy5.5-PerCP (SK1), anti-IL2 APC, anti-IFN  Alexa Fluor 700 (B27), anti-
TNF  Cy7-PE (MAb11) and anti-Ki67 PE (eBio64CAP17). In the OG-based 
proliferation assay, anti-CD3 Qdot 605 (UCHT1) was used in place of anti-CD3 
FITC (Leu-1). 
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All Abs were obtained from BD Bioscience, except for anti-Ki67 PE and 
anti-IL17 Alexa Fluor 647 obtained from eBioscience, and anti-CD3 Qdot 605 
and anti-CD4 Qdot 605 obtained from Invitrogen. 
After 1h incubation FACS tubes containing labelled cells were washed 
with 2ml Perm/Wash buffer, centrifuged for 5min at 2000rpm, supernatant 
decanted and cells resuspended in 100 l of PBS. Acquisition was completed on 
a BD LSRII flow cytometer (BD Biosciences, San Jose, CA). 
 
 
2.2.7 Flow cytometric analysis 
Analysis of flow cytometry data was performed using FlowJo software version 
8.8.5 (Treestar, San Carlos, CA). Separate compensation tubes for each 
fluorochrome-conjugated monoclonal Ab were prepared by first adding one drop 
each of anti-mouse Ig,  and negative control (FBS) compensation beads (BD™ 
CompBeads Set Anti-Mouse Ig, ) followed by the appropriate monoclonal 
antibody. Anti-rat Ig,  and negative control (FBS) compensation beads (BD™ 
CompBeads Set Anti-Rat Ig, ) were used with the rat Ab anti-IL2 APC. Anti-CD3 
Pacific Blue (UCHT1) was used to compensate for ViViD. In a dye dilution 
method where cells were stained with OG, anti-IL2 FITC (clone 5344.111) was 
used to compensate for OG. Compensation beads were stained at 4 C for 1h in 
the dark to allow labelling. 
Background fluorescence was determined automatically from single 
stained compensation beads, and compensation levels adjusted manually if 
necessary. Forward scatter area (FSC-A) versus forward scatter height (FSC-H) 
was used to exclude doublets and to gate on singlet cells followed by further 
analysis.  
To analyse flow cytometry data from the WB-ICC assay, a lymphocyte 
gate was made by plotting FSC-A versus side scatter area (SSC-A). Total T cells 
were gated on by plotting CD3+ events versus IFN- followed by a CD4+ versus 
CD8+ plot. Total cytokines produced by either CD4+ or CD8+ T cells were 
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determined by Boolean analysis of all possible combinations (see Chapter 3, Fig. 
3.1A). 
After excluding doublets in data from the 6 day PBMC proliferation assay, 
live cells were gated on by plotting the viability marker ViViD versus CD3+ 
events. The proliferation of live cells dim for ViViD and positive for CD3 were 
then analysed by plotting CD8 versus Ki67 or CD8 versus OG. This was followed 
by gating on CD8+ Ki67+/CD8+ OGlow and CD8- Ki67+/ CD8- OGlow proliferating 
cells. CD4+ T cells were defined as CD3+CD8- lymphocytes. Total cytokines 
produced by either of these proliferating cell populations was determined by 
Boolean analysis of all possible combinations. Cytokine expression was 
expressed as the frequency of grandparent, i.e. the percentage of live cytokine-
producing and proliferating T cells within the total CD4+ or CD8+ population 
Gates for proliferating and cytokine-producing cells were based on the 
negative control sample. 
 
 
2.2.8 Statistical analysis 
A response in the WB-ICC data assay was considered positive if it was greater 
than the median plus 3 times the median absolute deviation (Median + 3MAD) of 
the negative control samples. Background subtraction of proliferation data was 
based on the PMA/I negative control. Infants were excluded if the absolute 
number of viable CD3+ cells acquired was below the 25th percentile of viable 
CD3+ cells acquired in the negative control, i.e <5,000 cells. Eleven infants failed 
to meet this cut-off and where excluded from further analysis. A response was 
considered positive if the number of proliferating cells in the stimulated sample 
was at least >20 cells above background proliferation in the negative control. 
Proliferative response was expressed as a stimulation index (SI) by dividing the 
percentage of Ki67+ T cells in the BCG-stimulated sample by the percentage of 
Ki67+ T cells in the unstimulated (PMA/I negative control) sample. Data for both 
assays were excluded if the positive control failed to work. Data were analysed in 
Pestle v1.6.2 (Dr M. Roederer, VRC/National Institutes of Allergy and Infectious 
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Diseases/National Institutes of Health, Bethesda, MD) and Spice v 5.0.5013 
software (Dr M. Roederer and Joshua Nozzi, National Institutes of Allergy and 
Infectious Diseases/National Institutes of Health). A nonparametric Spearman 
test was used to determine associations between cytokine responses and birth 
weight. The Mann-Whitney test was used for comparisons between 2 groups and 
the Kruskal-Wallis test for comparisons between 3 groups.  A p value p<0.05 was 
considered significant. Statistical analysis was performed using GraphPad prism 
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BCG, the only currently licensed tuberculosis (TB) vaccine, provides variable 
protection against TB. Immunogenicity studies have indicated a wide range in the 
frequencies of specific T cells induced by BCG vaccination, and one of the host 
factors that could contribute to this variability is birth weight. We designed a study 
to determine if birth weight (BW) and gestational age (GA) affect the magnitude 
and quality of the BCG-induced immune response. We hypothesised that BCG-
vaccinated pre-term [PT (<37 weeks gestation)] and low birth weight [LBW 
(<2,500g)] infants would have a qualitatively and quantitatevely less optimal 
immune response, compared to term or normal birth weight (NBW) infants. 
105 healthy infants were enrolled from Worcester, South Africa and BCG 
vaccinated at birth. Infants were stratified by birth weight, GA, size for GA and 
gender. At 10 weeks of age, a whole blood intracellular cytokine assay and multi-
parameter flow cytometry was used to measure the BCG-induced immune 
response. 
Compared with NBW infants, LBW infants had a lower overall frequency of 
IL-2+ and TNF-a+ BCG-specific CD4 T cells, and a positive correlation was 
observed between the frequency of BCG-specific IL-2+ CD4+ T cells and birth 
weight. Moreover, we observed a lower proportion of polyfunctional BCG-specific 
CD4+ T cells and corresponding higher proportions of single cytokine-producing 
CD4 T cells expressing IFN- only, in LBW compared to NBW infants. 
These data suggest that LBW infants may have a reduced capacity to 
induce BCG-specific polyfunctional CD4+ T cells. The presence of these cells, 
following vaccination, has been associated with improved outcome in murine 
models following experimental TB infection. These results suggest that birth 
weight at time of vaccination may affect the quality of the BCG-induced immune 
response, and warrant further investigation in larger cohorts, and may ultimately 
have important implications for infant vaccination practices worldwide.  
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3.2 Introduction 
Mortality due to infectious disease is high, with an estimated 4 million infant 
deaths annually, which occur most frequently in developing countries within the 
neonatal period soon after birth (Garcia, Fadel et al. 2000; Bonhoeffer, Siegrist et 
al. 2006). Immunisation is one of the most important interventions in containing 
infectious diseases (Baley and Leonard 2005). More than 15% of infants are born 
pre-term [PT (<37 weeks gestation)], or have low birth weights [LBW (<2,500g)], 
with >90% of these born in developing countries (Okan, Karagoz et al. 2006). 
Vaccine administration may be delayed in PT and LBW infants, or may not occur 
at all, leading to higher morbidity rates compared to term and normal birth weight 
(NBW [≥2,500g]) infants. Delays are usually due to a belief that factors such as 
birth weight, current weight, or degree of prematurity should influence the timing 
of immunisations. Only later in life do vaccination rates for both PT and LBW 
infants increase to similar rates to that of term and NBW infants (Langkamp, 
Hoshaw-Woodard et al. 2001; Baley and Leonard 2005; Batra, Eriksen et al. 
2009). On the other hand vaccinating PT and LBW infants early in life may 
induce sub-optimal immune responses due to their developing immune systems 
(see Chapter 1, 2.0).  Thus it is important to fully characterise vaccine-induced 
immune responses in PT and LBW infants to optimise vaccination strategies in 
order to decrease morbidity rates in this group of infants.  
As discussed in Chapter 1 the neonatal immune system may be immature 
compared to adults, for example neonatal antigen presenting cells are inefficient 
at promoting Th1 responses and activating naïve T cells. Immaturities may be 
even more pronounced in PT and LBW infants. There is a gradual maturation of 
the immune system from birth to adulthood that may affect vaccine induced 
immune responses (see Chapter 1, 2.0). A study by Kagina et al on delaying 
BCG vaccination from birth to 10 weeks highlights the importance of maturational 
changes in the immune system that comes with age. Healthy term NBW infants 
were BCG vaccinated at birth or at 10 weeks of age. At 10, 20 and 50 weeks 
post-vaccination blood was collected and responses measured in a WB-ICC 
assay. Kagina et al observed that infants vaccinated at 10 weeks had greater 
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frequencies of BCG-specific CD4+ T cells, in particular polyfunctional BCG-
specific CD4+ T cells co-expressing IFN- , TNF-  and IL-2. These differences 
persisted and were most significant at 50 weeks post vaccination (Kagina, Abel 
et al. 2009). Kagina et al’s results showed an enhanced BCG-specific qualitative 
response in infants vaccinated at 10 weeks of age, implying that they are 
immunologically more mature than infants at birth.  
Compared to vaccination at birth, PT and LBW infants have been shown 
to mount a protective immune response following vaccination at 2 months of age, 
as shown by several studies that have evaluated protective antibody (Ab) titre 
levels to DTP (diptheria, tetanus, pertussis), hepatitis B, poliovirus and 
Haemophilus influenzae type b (Hib). However, these protective vaccine induced 
immune responses are frequently lower than those of term infants, and medically 
unstable PT LBW infants may also have lower Ab titres to these vaccines (Kim, 
Chung et al. 1997; Patel, Butler et al. 1997; Schloesser, Fischer et al. 1999; 
Baley and Leonard 2005). Previous studies have indicated that adequate levels 
of protective Ab titres to serotype 3 polio vaccine may be reduced in PT and LBW 
infants compared to term infants (D'Angio, Maniscalco et al. 1995). In general the 
same vaccination guidelines for term NBW infants may be applied to PT and 
LBW infants, with some exceptions (Esposito, Serra et al. 2009). Hepatitis B 
recommendations are complex and are based on the mothers’ hepatitis B 
infection status and the infant’s birth weight; infants weighing 2,000g are less 
likely to have protective levels of neutralising Ab compared to infants weighing 
≥2,000g (Baley and Leonard 2005). These studies highlight the variations in PT 
and LBW infant immune responses and show that under certain conditions, birth 
weight and gestational age (GA) may lead to a suboptimal response to some 
childhood vaccines.  
Tuberculosis (TB) kills 1.7 million people worldwide each year, and South 
Africa has the fifth highest incidence of the disease in the world. We focused on 
assessing the immune response to Bacillus Calmette-Guérin (BCG), the only 
currently licensed TB vaccine, which is administered at birth to all infants in 
South Africa. Studies in term infants have shown that BCG effectively protects 
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against severe childhood forms of TB disease (Trunz, Fine et al. 2006), however 
it is not clear if birth weight and maturity influence BCG immunogenicity (Okan, 
Karagoz et al. 2006). In TB endemic areas such as South Africa, infants should 
be vaccinated as soon as possible after birth (Fine, Carneiro et al. 1999). The 
World Health Organisation (WHO) recommends that PT infants should be 
vaccinated at the chronological age of 40 weeks, a practise seldom followed. 
Problems associated with calculating gestational ages (GA) result in BCG being 
administered when infants reach a birth weight of ≥2,500g, instead of when they 
reach a chronological age of 40 weeks, as proposed by the WHO (Roth, Jensen 
et al. 2004). 
Previous studies on the immune responses to BCG vaccination in PT and 
LBW infants have yielded conflicting conclusions. Sedaghatian et al suggested 
that PT infants vaccinated at birth have a lower response to BCG as indicated by 
poor BCG scar formation, and low responses to tuberculin purified protein 
derivative (PPD). In this study, 101 PT infants were BCG vaccinated at birth and 
responses measured 2-4 months later. Overall, 32% did not develop a BCG scar 
following vaccination, and of the 70 infants that returned for tuberculin skin test 
measurements, 31% were non-reactive (Sedaghatian and Kardouni 1993). In 
contrast, in a study of 35 PT infants vaccinated at 2-3 months of age, Okan et al 
found high rates of BCG scarring and positive TST conversion (Okan, Karagoz et 
al. 2006). However these two studies by Okan et al and Sedaghatian et al were  
limited in not having a control group of term infants.  In yet another study by 
Sedaghatian et al, PT immune responses to BCG were compared to term infants. 
BCG scarring was found to be largest in term infants vaccinated at birth, 
compared to PT infants vaccinated at birth or at 40 weeks of age. When these 3 
groups of vaccinated infants were further analysed, BCG scarring and TST 
measurements were found to be associated with sex and birth weight. Female 
infants were more likely to have a BCG scar and a positive TST conversion 
(Sedaghatian, Hashem et al. 1998). Negrete-Esqueda et al found similar 
responses to TST and rates of BCG scarring when 50 PT and 50 term infants 
BCG vaccinated at birth were directly compared, concluding that PT infants may 
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be BCG vaccinated at birth (Negrete-Esqueda and Vargas-Origel 2007). Others 
have also compared subgroups of term infants to determine the effect of intra 
uterine growth restriction (IUGR). Using TST measurements, 57 term, small for 
gestational age (SGA) infants were compared to 52 term, appropriate for 
gestational age (AGA) infants and immunogenicity to BCG was found to be 
similar between the two groups (Mussi-Pinhata, Goncalves et al. 1993).  
Previous studies of BCG-induced immune responses in PT and LBW 
infants have measured immunity by Elisa, lymphoproliferation assays, TST and 
the presence of a BCG scar. One disadvantage of these bulk assay approaches 
is that a more detailed analysis of specific responses on a single cell level is not 
possible (Thiel, Scheffold et al. 2004). Not only have these few studies either 
been inconclusive or yielded conflicting results, they have also highlighted the 
wide variation in infant immune responses to BCG. Differences in methodology 
may also explain in part the conflicting and variable results obtained in previous 
studies. In addition, TST reactivity after BCG vaccination is is not generally 
thought to influence the degree of protection offered by BCG, and up to 25% of 
infants do not develop a BCG scar following vaccination (al-Kassimi, al-Hajjaj et 
al. 1995; Negrete-Esqueda and Vargas-Origel 2007).  
Recently, the use of intracellular cytokine staining and multiparameter flow 
cytometry has allowed the detailed study of antigen-specific immune responses 
on a single cell basis (Suni, Picker et al. 1998), and has been applied to the 
study of mycobacteria-specific responses (Hanekom, Hughes et al. 2004; 
Hanekom 2005; Soares, Scriba et al. 2008; Kagina, Abel et al. 2009). These 
studies on term, NBW infants and adults have shown detectable functional BCG-
specific CD4+ and CD8+ T cells of varying frequency that express complex 
patterns of IFN- , IL-2 and TNF-  cytokines (Murray, Mansoor et al. 2006; 
Soares, Scriba et al. 2008). The T-helper type 1 (Th1) cytokines such as IFN- , 
IL-2 and TNF-  have been used routinely to measure BCG immunogenicity 
(Marchant, Goetghebuer et al. 1999; Murray, Mansoor et al. 2006; Kagina, Abel 
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et al. 2010). However, these studies have not addressed the effect of maturity 
and birth weight on the cytokine profile of BCG-induced T cell responses.  
In conclusion, studies to date have not fully addressed BCG induced 
immune responses in PT and LBW infants. These infants may miss out on the 
BCG induced protective effects against severe childhood forms of TB. 
Considering the high PT and LBW rates in developing countries, we investigated 
the effect of GA and birth weight on BCG immunogenicity. We aimed for the first 
time to assess the BCG induced T cell responses of medically stable PT and 
LBW infants on a single cell basis using a whole blood intracellular cytokine 
staining assay and multiparameter flow cytometry. We hypothesised that BCG 
vaccinated PT and LBW infants have a lower frequency of BCG-specific T cells 
compared to term or NBW infants. A better understanding of the effects of birth 
weight and GA on the BCG induced immune response may ultimately lead to 














3.3.1 Participant characteristics 
One hundred and five BCG vaccinated, healthy infants were enrolled in the 
study. Blood was collected at 10 weeks of age from infants who were stratified 
according to birth weight, gestational age, gender and maturity (see Materials 




Table 3.1. Study participant characteristics 
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3.3.2 Flow cytometric detection of BCG-specific T cell responses in whole blood 
To investigate the effect of birth weight on the frequency and profile of BCG-
specific T cells in infants 10 weeks post-vaccination, BCG-stimulated cells from a 
WB-ICC assay (see Materials and Methods, 2.2.4) were thawed and analysed by 
multiparameter flow cytometry. The sequential gating strategy (Fig. 3.1A) was 
used to delineate different cell types (CD3+/CD3-), cell subsets (CD4+/CD8+) 
and intracellular cytokines expressed (IL-2, TNF- , IFN-  and IL-17). 
Representative intracellular cytokine staining data for CD4+ T cells from a LBW 
and NBW infant are shown (Fig. 3.1B). Cytokine gates were based on the 
unstimulated sample and were kept constant for each infant’s corresponding 
SEB and BCG stimulated condition. All infants responded to SEB stimulation. We 
observed that both LBW and NBW 10-week old infants BCG vaccinated at birth 
had a detectable specific immune response to BCG using the WB-ICC assay. 
Antigen specificity of this assay in detecting BCG-induced responses in 10-week 
old BCG vaccinated infants has been shown previously in a study by Kagina et 
al, who showed that BCG vaccinated but not unvaccinated infants display BCG-






Figure 3.1. Flow cytometry gating strategy and representative data from the whole blood 
intracellular cytokine staining (WB-ICC) assay. (A) Gating is first performed on singlets then 
lymphocytes, followed by CD3+ T cells, from which CD4+ and CD8+ T cells are differentiated. In 
(B) the percentage of CD4+ T cells expressing combinations of IL-2, IFN- , TNF-  or IL-17 
cytokines are shown for a low birth weight (LBW) and normal birth weight (NBW) infant; 
percentages shown on the plots are prior to subtraction of cytokine production in the negative 
control sample. Representative data are shown from a negative control (unstimulated), BCG and 
SEB stimulated sample.  
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3.3.3 Frequency of BCG-specific CD4+ T cells expressing Th1 and Th17 
cytokines. 
Expression of the T-helper type 1 (Th1) cytokines IL-2, IFN-  and TNF-  has 
been frequently used to measure BCG immunogenicity (Marchant, Goetghebuer 
et al. 1999; Murray, Mansoor et al. 2006; Soares, Scriba et al. 2008; Kagina, 
Abel et al. 2010). There is increasing evidence that Th17 cells play an important 
role in M.tb infection (Chen, Zhang et al.). Recently, the presence of BCG-
specific CD4+ Th17 cells expressing IL-17 was shown for the first time in whole 
blood of infants following BCG vaccination (Kagina, Abel et al. 2010). 
We therefore assessed the total frequency of BCG-specific CD4+ T cells 
producing IL-2, IFN- , TNF-  or IL-17, and compared responses between LBW 
and NBW infants. NBW infants had a higher total frequency of BCG-specific IL-2 
and TNF producing CD4+ T cells than LBW infants (Fig. 3.2A). No differences 
between LBW and NBW infants were found in the total BCG-specific CD4+ T cell 
expression of IFN-  or IL-17.  
To determine whether birth weight influenced the rate of detection of BCG-
specific CD4+ T cell responses, we compared the percentage of infants with a 
positive BCG-specific CD4+ T cell response between LBW and NBW infants. 
Determination of a positive response is described in Materials and Methods, 
2.2.1. All NBW infants and 96% of LBW (n=50) infants had a detectable BCG-
specific CD4+ T cell response above background (Fig. 3.2B). There was no 
difference in the frequency of BCG-specific CD4+ T cell responders between 
NBW and LBW infants. These results indicate that birth weight alone does not 
affect the ability to detect BCG-specific CD4+ T cell responses ex vivo in our 




Figure 3.2. (A) Frequency of BCG-specific CD4+ T cells expressing cytokines in LBW (n=52) and 
NBW (n=53) infants. The horizontal line represents the median and the boxes represent the 
interquartile range. The Mann Whitney test was used to calculate statistical differences between 
individual groups. (B) The percentage of vaccinated infants with a detectable BCG-specific CD4+ 
T cell response above background. Out of 52 LBW and 53 NBW infants, CD4+ T cells from 50 
LBW (96%) and 53 NBW (100%) infants responded to BCG. There was no statistical difference 
between the percentages of infants responding to BCG (Fisher’s exact test). 
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3.3.4 Association between birth weight and gestational age and total frequencies 
of BCG-specific cytokine+ CD4+ T cells 
The analyses described above were done by categorically grouping infants as 
either LBW or NBW. We next investigated whether there was a direct correlation 
between BCG-specific responses and birth weight as a continuous variable (Fig. 
3.3). We found a positive association between the total frequency of BCG-
specific CD4+ T cells expressing IL-2 and birth weight (Fig. 3.3A). No 
associations were found with birth weight and total frequencies of BCG-specific 
CD4+ T cells producing IFN- , TNF-  or IL-17 (Fig. 3.3B-D).  
 
 
Figure 3.3. Correlation between the birth weight of 105 BCG vaccinated infants and the 
frequency of BCG-specific CD4+ T cells expressing either: (A) IL-2, (B) IFN- , (C) TNF-  or (D) 
IL-17. Statistical significance was calculated using the Spearman test. 
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To assess the influence of GA, we investigated the association between 
the frequency of BCG-specific CD4+ T cell responses and GA (Fig. 3.4). 
Although there was a positive association between CD4+ T cells expressing IL-
17 and GA (Fig. 3.4D), no associations were found between GA and any of the 
Th1 cytokines measured (Fig. 3.4A-C). These results suggest that birth weight 
may have a greater influence on BCG immunogenicity than GA.  
 
 
Figure 3.4. Correlation between the gestational ages of 105 BCG vaccinated infants and 
frequency of BCG-specific CD4+ T cells expressing either: (A) IL-2, (B) IFN- , (C) TNF-  or (D) 
IL-17. Statistical significance was calculated using the Spearman test. 
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3.3.5 Effect of birth weight on the cytokine profile of BCG-specific CD4+ T cell 
responses 
After evaluating the effects of birth weight on the total frequency of cytokine+ 
BCG-specific CD4+ T cells, we next assessed the patterns of co-expression of 
multiple cytokines in individual T cells. We used multiparameter flow cytometry to 
measure individual BCG-specific CD4+ T cells expressing combinations of IL-2, 
IFN- , TNF-  or IL-17. Boolean analysis of these produced 15 distinct cytokine 
expressing T cell subsets, providing a detailed analysis of the functional capacity 
of these BCG-specific T cells. 
We first compared the frequency of BCG-specific CD4+ T cells expressing 
combinations of IL-2, IFN- , TNF-  or IL-17 in NBW and LBW infants. Similar 
frequencies of CD4+ T cells expressing combinations of these cytokine 
populations were found in the two groups of infants (Fig. 3.5A). Consistent with 
previous findings, the predominant BCG-specific response in both groups was 
that of single cytokine-producing CD4+ T cells expressing IFN- only and 
polyfunctional CD4+ T cells co-expressing IFN- , TNF-  and IL-2 together 
(Soares, Scriba et al. 2008; Kagina, Abel et al. 2009). We next addressed the 
quality of the response by assessing the contribution of each subset of cytokine-
producing cells to the total BCG-specific CD4+ T cell response. For this analysis, 
we only analyzed infants with a detectable BCG-specific CD4+ T cell response 
(see Materials and Methods, 2.2.1). Using these criteria, we excluded 2 LBW 
infants whose BCG-specific CD4+ T cell response was not above background 
levels. We then compared the proportion of BCG-specific CD4+ T cell subsets 
expressing 15 different combinations of IL-2, IFN- , TNF-  or IL-17 in NBW 
(n=53) and LBW (n=50) infants (Fig. 3.5B). In both groups of infants the 
predominant BCG-specific cytokine-producing subsets were CD4+ T cells 
expressing IFN- only and CD4+ T cells co-expressing IFN- , TNF-  and IL-2 
together. However, LBW infants had a lower proportion of polyfunctional BCG-
specific CD4+ T cells co-expressing IFN- , TNF-  and IL-2 together, compared to 
NBW infants, and correspondingly higher proportions of single cytokine-
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producing CD4+ T cells expressing IFN- only. Lastly, LBW infants had a lower 
proportion of BCG-specific CD4+ T cells co-expressing IFN-  and TNF-  together 
compared to NBW infants. Notably, when IL-17 was measurable, it was found to 
be expressed alone (Fig. 3.5). These results suggest that LBW infants may have 
a reduced capacity to induce polyfunctional CD4+ T cells following BCG 
vaccination. Although we found differences by grouping infants categorically as 
either LBW or NBW, there was no direct correlation between the proportion of 
BCG-specific CD4+ T cells co-expressing IFN- , TNF-  and IL-2 together or 
single cytokine-producing BCG-specific CD4+ T cells expressing IFN- only and 
birth weight (data not shown). The same analysis was done by gestational age 
and no association was found (data not shown). 
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Figure 3.5. The frequency and proportion of BCG-specific CD4+ T cells expressing combinations 
of IL-2, IFN- , TNF-  or IL-17 in LBW and NBW infants. The frequency (A) of CD4+ T cells 
expressing combinations of cytokines for all infants is shown (LBW, n=52 and NBW, n=53 
respectively). Only infants with a detectable BCG-specific CD4+ T cell response above 
background (LBW, n=50 and NBW, n=53; see Materials and Methods, 2.2.8) were included when 
calculating the proportion of BCG-specific CD4+ T cells expressing each combination of 
cytokines (B). The horizontal line represents the median and the boxes represent the interquartile 
range. Each pie is divided into 3 slices that represent the median proportion of the total BCG-
specific CD4+ T cell response, a slice each for T cells expressing a combination of 3, 2 or 1 
cytokine only (B).  The Mann Whitney test was used to calculate statistical significance between 
the individual groups. 
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3.3.6 Size for gestational age, maturity and gender do not affect the cytokine 
profile of BCG-specific CD4+ T cell responses 
As we observed a difference in the proportion of specific cytokine-producing 
subsets contributing to the total BCG-specific CD4+ T cell response between 
NBW and LBW infants, we performed a similar analysis in infants stratified into 3 
groups: size for gestational age, maturity and gender. For this analysis, we only 
analyzed infants with a detectable BCG-specific CD4+ T cell response (see 
Materials and Methods, 2.2.1). We excluded 2 male infants who were not BCG 
responders, both of whom were small for gestational age, 1 was term and the 
other pre-term. We thus evaluated responses in small for gestational age (SGA; 
n=42), appropriate for gestational age (AGA; n=47), large for gestational age 
(LGA; n=14), term (n=65), pre-term (n=38), male (n=51) and female (n=52) infant 
BCG responders. The proportion of polyfunctional BCG-specific CD4+ T cells co-
expressing IFN- , TNF-  and IL-2 together (Fig. 3.6A), co-expressing IFN-  and 
TNF-  together (Fig. 3.6B), and single cytokine-producing BCG-specific CD4+ T 
cells expressing IFN- only (Fig. 3.6C), were not different by size for GA, maturity 
or gender. We also compared the proportion of BCG-specific CD4+ T cells 
expressing all other combinations of IL-2, IFN- , TNF-  or IL-17 and found no 
differences (data not shown). We concluded that the qualitative response to BCG 




Figure 3.6. Proportions of polyfunctional BCG-specific CD4+ T cells stratified by size for 
gestational age, term status, and sex. The proportions of BCG-specific CD4+ T cells co-
expressing IL-2, IFN-  and TNF-  cytokines together (A), co-expressing IFN-  and TNF-  
cytokines only (B), or expressing IFN-  only (C) are shown. Only infants that responded to BCG 
are shown and were stratified as follows: small for gestational age (SGA; n=42), appropriate for 
gestational age (AGA; n=47), large for gestational age (LGA; n=14), term (n=65), pre-term 
(n=38), male (n=51) and female (n=52). The horizontal line represents the median and the boxes 
represent the interquartile range. The Mann Whitney test was used for comparisons between two 




3.3.7 Frequency of BCG-specific CD8+ T cells. 
Following BCG vaccination, BCG-specific CD8+ T cells are induced (Murray, 
Mansoor et al. 2006; Soares, Scriba et al. 2008). As we observed a difference in 
the total frequency of TNF-  and IL-2-producing BCG-specific CD4+ T cell 
responses by birth weight, we next investigated whether the BCG-specific CD8+ 
T cell response was affected by birth weight.  
We assessed the total frequency of BCG-specific CD8+ T cells expressing 
cytokines in NBW and LBW infants. There was no difference in the total 
frequencies of BCG-specific CD8+ T cells producing IL-2, IFN- , TNF-  or IL-17 
between LBW and NBW infants (Fig. 3.7A). We also compared the percent 
frequency of responders between LBW and NBW infants. After applying a cut-off 
for a positive BCG-specific CD8+ T cell response (see Materials and Methods, 
2.2.1), 77% of NBW infants (n=41) and 75% of LBW infants (n=39) had a 
detectable BCG-specific CD8+ T cell response in our assay system (Fig. 3.7B). 
We concluded that equal numbers of infants responded to BCG vaccination as 
measured by our assay system, and that birth weight does not affect the 




Figure 3.7. (A) Frequency of BCG-specific CD8+ T cells expressing cytokines in LBW and NBW 
infants. The horizontal line represents the median and the boxes represent the interquartile 
range. There was no statistical difference as determined by the Mann Whitney test. (B) The 
percentage of vaccinated infants with a detectable BCG-specific CD8+ T cell response above 
background levels. Out of a total of 105 infants, 39 LBW (75%) and 41 NBW (77%) infants had a 
detectable CD8+ T cell response to BCG. There was no statistical difference between the 
percentages of infants responding to BCG (Fisher’s exact test). 
 
 64 
3.3.8 There is no association between both birth weight and gestational age and 
CD8+ T cells expressing IL-2, IFN- , TNF-  or IL-17 
An association between both birth weight (Fig. 3.8) and gestational age (data not 
shown) and total frequencies of cytokine-producing, BCG-specific CD8+ T cells 
in 105 infants was investigated. No correlations were found between birth weight 
and the total frequency of BCG-specific CD8+ T cells expressing the cytokines 
IL-2, IFN- , TNF-  or IL-17.  
 
 
Figure 3.8. Correlation between the birth weight of 105 BCG vaccinated infants and the 
frequency of BCG-specific CD8+ T cells expressing either IL-2 (A), IFN- (B), TNF-  (C), or IL-17 
(D). Statistical significance was calculated using the Spearman test. 
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3.3.9 The quality of BCG-specific CD8+ T cell responses is not affected by birth 
weight 
We compared the frequency of BCG-specific CD8+ T cells expressing all 
possible combinations of IL-2, IFN- , TNF-  or IL-17, and found no difference 
between NBW and LBW infants (Fig. 3.9A). Within infants with a detectable 
BCG-specific CD8+ T cell response (see Materials and Methods, 2.2.1), we next 
assessed the contribution of each subset of cells to the total BCG-specific CD8+ 
T cell response (Fig. 3.9B). There was no difference in the proportion of BCG-
specific CD8+ T cells expressing combinations of IL-2, IFN- , TNF-  or IL-17. A 
similar analysis was done for infants stratified according to their size for GA, 
maturity and gender but no differences in BCG-specific CD8+ T cell responses 
were found (data not shown). The BCG-specific CD8+ T cell responses were 
notably smaller in magnitude and the profile less complex compared to BCG-
specific CD4+ T cell responses. Consistent with previous reports (Soares, Scriba 
et al. 2008; Kagina, Abel et al. 2009; Kagina, Abel et al. 2010) the most dominant 
BCG-specific response was that of single cytokine-producing CD8+ T cells 
expressing IFN- only. These results indicate that the magnitude and quality of 
the cytokine+ BCG-specific CD8+ T cell response is not affected by birth weight, 





Figure 3.9. The frequency (A) and proportion (B) of BCG-specific CD8+ T cells expressing 
combinations of IL-2, IFN- , TNF-  or IL-17 cytokines in LBW and NBW infants. Only infants with 
a detectable BCG-specific CD8+ T cell response above background (LBW, n=39 and NBW, 
n=41) were included in the proportions of the total BCG-specific CD8+ T cell response shown in 
(B). The horizontal line represents the median and the boxes represent the interquartile range. 
Each pie is divided into 3 slices that represent the median proportion of the total BCG-specific 
CD8+ T cell response, a slice each for T cells expressing a combination of 3, 2 or 1 cytokine only 




To improve the efficacy of the BCG vaccination program, it is important to 
evaluate its effects in susceptible populations such as PT and LBW infants. It is 
not known if maturity or birth weight influences the functional quality of BCG-
specific T cell responses. Varying results on the immunogenicity of the vaccine in 
PT and LBW infants as assessed by BCG scarring and the Mantoux test raises 
questions about interpretability of the results of these studies. To perform a 
detailed characterization of BCG-specific T cell responses in PT and LBW 
infants, we used multiparameter flow cytometry, a more sensitive and specific 
assay that could measure immune responses on a single cell basis. This is the 
first study using this assay system to report these responses in PT and LBW 
infants who were BCG vaccinated at birth. We report that following BCG 
vaccination, LBW infants have an altered BCG induced immune response, 
characterised by an increased proportion of monofunctional BCG-specific CD4 T 
cells producing IFN-  in LBW infants.  
Consistent with previous findings, we were able to measure BCG-specific 
T cell responses of 10-week-old infants using a WB-ICC assay and 
multiparameter flow cytometry. Similar to previous findings, BCG-specific CD4+ T 
cells were predominantly either IFN-  single positive or polyfunctional cells co-
expressing IFN- , TNF-  and IL-2, whereas BCG-specific CD8+ T cells were 
predominately IFN-  single positive only (Hanekom 2005; Soares, Scriba et al. 
2008; Kagina, Abel et al. 2009). It is unlikely that infants enrolled in the study had 
significant exposure to environmental mycobacteria by the time we collected 
blood at 10-weeks of age. Kagina et al’s delayed BCG vaccination study outlined 
in the introduction section of this chapter supports this view. BCG-specific 
responses measured in whole blood at 10 weeks of age in the delayed group, 
before they were BCG vaccinated, were very low or undetectable but were 
readily detectable in infants BCG vaccinated at birth (Kagina, Abel et al. 2009). 
We can thus assume that the responses we measured were specific and not 
affected by environmental mycobacteria. Bacterial superantigens produced by 
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Staphylococcus aureus such as SEB, our positive control in this study, are potent 
T cell mitogens activating up to 20% more T cells than conventional Ag (Chaplin 
2010). Superantigens including SEB stimulate large numbers of T cells by 
binding to the TCR and MHC class  molecules outside of their conventional 
binding sites leading to massive cytokine production, particularly IFN- , TNF-  
and IL-2. They also have the advantage of activating rare populations of T cells 
(Fraser and Proft 2008). Conventional Ag on the other hand specifically bind a 
small subset of TCR and MHC molecules thus activating only small numbers of T 
cells (Chaplin 2010). All infants in our study responded to SEB stimulation and 
SEB-specific responses were similar when we compared infants by variables 
such as birth weight, gestational age, size for GA or gender. These data suggest 
there was no global functional deficiency in the infant immune systems, at least 
for the particular Th1 and Th17 cytokines measured here. As SEB responses 
were similar, then differences in BCG-specific responses could be attributed to 
either of the aforementioned variables. 
We studied CD4+ T cells as they have been shown to be induced upon 
BCG vaccination and are widely believed to be essential in anti-mycobacterial 
immunity (Boom, Canaday et al. 2003; Flynn 2004; Cooper 2009). Compared 
with NBW infants, LBW infants had a lower overall frequency of BCG-specific 
CD4+ T cells expressing IL-2 and TNF-  Furthermore, a positive correlation was 
observed between the frequency of IL-2+ BCG-specific CD4+ T cells and birth 
weight. Vaccination aims to induce immunological memory and IL-2 expression is 
important for T cell memory induction and maintenance (Williams, Tyznik et al. 
2006). T cells in the elderly express low levels of IL-2 and can be used to 
illustrate the importance of this cytokine. These cells show a markedly decreased 
ability to induce effector T cells and functional T cell memory, properties rescued 
by addition of exogenous IL-2 (Linton, Haynes et al. 1996; Haynes, Linton et al. 
1999; Haynes, Eaton et al. 2003; Haynes, Eaton et al. 2004). Presumably the 
decreased expression of IL-2 in LBW infants is suboptimal, and if it persists this 
may ultimately result in BCG-induced cells with impaired proliferative capacity. 
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Our assay system predominantly measures an effector response, thus further 
studies on the memory T cell phenotype induced by BCG in PT and LBW infants 
are warranted. Reactivation of latent TB individuals undergoing anti-TNF  
treatment for rheumatoid disorders highlights the importance of this cytokine in 
host resistance against M.tb infection (Bruns, Meinken et al. 2009). These data 
suggests that NBW infants may develop a better qualitative response to BCG 
vaccination. However, the association of these cytokines with birth weight 
requires further study.  We found no differences in the expression of IFN- , a 
cytokine commonly used as a measure of BCG immunogenicity. Humans with 
congenital mutations in IFN- -associated signalling pathways or receptors are 
more susceptible to mycobacteria infections, thus providing evidence for the 
importance of this cytokine (van de Vosse, Hoeve et al. 2004).  
Through a more comprehensive analysis of BCG-specific responses on a 
single cell basis, we showed that LBW infants have a lower proportion of BCG-
specific polyfunctional CD4+ T cells co-expressing IFN- , TNF-  and IL-2 
together, and corresponding higher proportions of single cytokine-producing 
CD4+ T cells expressing IFN- only. Our results suggest that birth weight at the 
time of vaccination may affect the quality of the BCG-induced immune response. 
Induction of high frequencies of polyfunctional T cells co-expressing IFN- , TNF-
 and IL-2 together have been associated with improved outcome in murine 
models following experimental TB infection (Forbes, Sander et al. 2008). 
Interestingly, there was no direct correlation between the proportion of 
polyfunctional cells and birth weight, although there was a trend towards higher 
proportions of polyfunctional CD4+ T cell responses by birth weight. Thus the 
association of birth weight and the proportion of BCG-specific polyfunctional 
CD4+ T cells require further study. As discussed in chapter 1, neonatal APCs 
have been shown to express low levels of costimulatory molecules. Although we 
were not able to measure expression of costimulatory molecules in this study, we 
hypothesise that expression of these molecules may have been reduced in our 
cohort of LBW infants. Priming of BCG specific responses in LBW infants may 
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have led to sub-optimal differentiation of BCG-specific T cell responses that were 
more monofunctional than polyfunctional in nature. This may explain our 
observation that LBW infants expressed higher monofunctional responses, 
characterised by a higher proportion of BCG-specific cells producing IFN-  only. 
We also measured BCG-specific CD4+ T cells expressing IL-17. To our 
knowledge this cytokine has never been studied in BCG vaccinated PT and LBW 
infants. This cytokine triggers chemokine expression in the lung, mediating the 
recruitment of protective Th1 cells and inducing inflammation in a murine 
vaccination model against TB (Khader, Bell et al. 2007). We did not observe a 
difference in the frequency of BCG-specific CD4+ IL-17+ T cells, however we did 
find an association between the frequencies of CD4+ T cells expressing IL-17 
and gestational age. We do not know whether the presence of IL-17 in older 
infants reflects a more optimal immune response as IL-17 induced inflammation 
may be detrimental. The WHO policy is that PT infants should be vaccinated 
when they reach the gestational age of 40 weeks, presumably when their 
immune systems have matured more. Interestingly, there was no association 
with gestational age and the Th1 cytokines IL-2, IFN-  or TNF-  that are routinely 
used as measures of BCG vaccine immunogenicity. 
After observing differences in CD4+ T cell responses by birth weight we 
also analyzed BCG-specific CD8+ T cell responses. CD8+ T cells have been 
detected previously in whole blood of BCG vaccinated infants (Davids, Hanekom 
et al. 2006; Murray, Mansoor et al. 2006). Experimental models of TB infection 
support the role of CD8+ T cells in protection against TB disease. For example, 
in BCG vaccinated rhesus macaques, depletion of CD8+ T cells results in 
increased bacterial counts and in a loss of BCG-induced protective immunity 
upon challenge with Mtb (Chen, Huang et al. 2009). The frequencies of CD8+ T 
cell responses, though lower than CD4+ T cell responses, were still readily 
detectable, consistent with previous reports (Soares, Scriba et al. 2008; Kagina, 
Abel et al. 2010). Mycobacterial Ags are primarily presented in the context of 
class  MHC molecules thus stimulating mainly CD4+ T cells. The contribution of 
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CD8+ T cells is thus likely to be under represented. No differences by birth 
weight were observed, suggesting that birth weight may have less of an effect on 
priming CD8+ T cell responses to BCG.  
Caution should be exercised when interpreting the biological and clinical 
significance of our results, which require further study. In a study by Kagina et al, 
blood was collected from 10-week old term, NBW infants who were BCG 
vaccinated at birth and where then followed up for at least 2 years for 
development of TB disease. They identified a group of infants that developed 
culture positive TB, despite having received BCG at birth. The BCG-specific T 
cell responses at 10 weeks of these unprotected infants were compared to that of 
control groups of infants that did not develop TB (Kagina, Abel et al. 2010). 
Kagina et al, using a whole blood assay and multiparameter flow cytometry, 
showed that the presence of polyfunctional BCG-specific CD4+ T cells co-
expressing IFN- , TNF-  and IL-2 did not correlate with protection against 
development of pulmonary TB in this cohort. In addition, the overall frequency of 
BCG-specific CD4+ T cells expressing IFN- , TNF- , IL-2 and IL-17 did not 
correlate with protection. In this study we did not measure δ T cells, which 
constitute a large proportion of neonatal T cells, and may play an important role 
in BCG-induced immunity. Kagina et al however found that the frequency of 
BCG-specific δ T cells did not correlate with protection (Kagina, Abel et al. 
2010). These studies suggest that the quantitatively greater BCG-specific T cell 
responses we measured in NBW infants may not necessarily afford a greater 
degree of protection against development of TB. Kagina et al enrolled infants 
from the same parent cohort that we selected our study participants from. This 
parent cohort consisted of 11,670 infants enrolled as part of a phase IV 
randomized control trial (RCT) testing the effect of vaccination route on BCG 
vaccine efficacy (Hawkridge, Hatherill et al. 2008). Infants chosen for our study 
were in the group of infants that did not develop TB when followed up for at least 
2 years. We are therefore unable to address the question of whether BCG 
protects PT and LBW infants against TB disease. Our study can only address 
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BCG-induced immunogenicity, and large-scale efficacy trials would be required 
to address the effects of maturity and birth weight on BCG-mediated protection 
against TB. However, the responses we measured, if based on the common 
opinion that qualitatively greater responses are protective, suggest that NBW 
infants may have a more optimal response to BCG than LBW infants. 
Overall, most cytokine expression patterns of BCG-specific cells were not 
affected by birth weight, gestational age, size for GA or gender. Our results 
reveal the complexity of BCG-induced immunity and of the relationship between 
birth weight, maturity and BCG-specific responses. These findings, in part, 
support our hypothesis that PT and LBW infants have a lower frequency of BCG-
specific T cells, compared to term and NBW infants. As discussed previously, 
immaturities in the neonatal immune system may be even more pronounced in 
PT and LBW infants and may potentially reduce vaccine specific responses. This 
may be the main reason explaining the altered BCG-specific immune response in 
PT and LBW infants observed in this study.  
Our findings may be unique to the selected cohort and thus we propose 
that these results should be confirmed in larger cohorts before future studies are 
performed to determine the effects of maturity and birth weight on BCG-mediated 
protection against TB. Another limitation of our study is that we only assessed 
BCG-specific responses at 10 weeks post vaccination. There is a possibility that 
when we collected blood at 10-weeks of age the immune systems of PT and 
LBW infants had matured sufficiently enough to result in the masking of 
differences in BCG-specific responses compared to term and NBW infants. It 
would be interesting in future studies to perform a longitudinal analysis of the 
cytokine profiles of BCG-induced T cell responses in LBW and NBW infants. This 
will address the question of whether the altered BCG-specific immune response 
we observed in PT and LBW infants is short-lived or if this alteration persists. 
Furthermore, analysis of BCG-specific T cell responses at time points earlier than 
10 weeks post-vaccination may shed light on important events early in priming of 
BCG-specific immune responses that may be influenced by either birth weight or 
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maturity. Despite these limitations, the findings of this preliminary study represent 
an important first step in helping policy makers optimize BCG vaccination 
policies. Optimal vaccination of PT and LBW infants will ultimately lead to better 
control of the TB epidemic. 
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CHAPTER FOUR 
The effect of birth weight and gestational age on the proliferative potential and 




Proliferation and clonal expansion upon secondary antigen exposure is an 
important feature of protective immunological memory. Measurement of antigen-
specific proliferative potential following vaccination is therefore important in 
assessing vaccine immunogenicity. We showed differences in BCG 
immunogenicity by birth weight on a single cell basis using a WB-ICC assay and 
multiparameter flow cytometry. This short-term assay measured cytokine 
production directly ex vivo, which is only one aspect of cellular responses. A 
different aspect is the proliferative potential and cytokine producing capacity of T 
cell, critical functions that may be affected by birth weight. We hypothesized that 
BCG vaccination at birth induces antigen-specific T cells with a greater 
proliferative and cytokine producing capacity in NBW infants. In assessing this 
attribute we compared 2 flow cytometry based methods of measuring 
proliferation, a Ki67 proliferation assay and dye dilution of Oregon green. Ki67 
expression allowed greater detection of antigen-specific proliferating and 
cytokine producing cells. Cryopreserved PBMC from 10-week old infants were 
thawed and cultured in a 6-day KI67 proliferation assay, followed by multi-
parameter flow cytometry analysis. No differences were found in the proliferative 
response and the capacity of proliferating BCG-specific T cells to express IFN- , 
TNF  and IL-2 in LBW and NBW infants. This preliminary data suggests that 
birth weight may not directly influence the proliferative response and cytokine 
production capacity of BCG-specific T cells as measured in a 6-day proliferation 




Proliferation and clonal expansion upon secondary antigen exposure is an 
important feature of protective immunological memory and is the basis of 
vaccination (Sprent and Surh 2002; Janeway 2005). Measurement of antigen-
specific proliferative potential following vaccination is therefore important, and 
has been widely used in assessing vaccine immunogenicity. The methods 
summarized in Chapter 2 have been commonly used to measure vaccine 
immunogenicity in vitro. These techniques, coupled with multiparameter flow 
cytometric analysis of antigen-specific proliferating cells, allow delineation of 
different cell types, cell subsets and the detection of cytokine expression. These 
include techniques based on uptake of radioactive nucleotides such as tritiated 
thymidine (3H), DNA incorporation of nucleotide analogues such as 
bromodeoxyuridine (BrdU), dye dilution assays and intracellular detection of the 
nuclear protein Ki67 (see Materials and Methods 2.1.2).  
The neonatal immune system differs from the adult immune system in 
certain regards and is widely considered to be immature. For example, a large 
proportion of neonatal T cells are in cycle and are susceptible to apoptosis, 
indicating a high rate of cell turn over (proliferation) (Hassan and Reen 2001; 
Schonland, Zimmer et al. 2003; Szabolcs, Park et al. 2003). Telomere length 
shortens with successive replication cycles (Harley, Futcher et al. 1990), but 
despite the high rate of proliferation, neonatal T cells maintain long telomere 
length. In addition, neonatal T cells display characteristics of recent migration 
from the thymus. Compared to adults, neonatal T cells have high concentrations 
of T-cell-receptor excision circles (Trecs), a marker of newly synthesized T cells 
(Hassan and Reen 2001; Schonland, Zimmer et al. 2003).  
The underlying differences in the proliferative potential of neonatal T cells 
may be even more pronounced in pre-term (PT) and low birth weight (LBW) 
infants, and may affect vaccine immunogenicity. Raqib et al found that compared 
to normal birth weight (NBW) infants, LBW infants showed a trend towards lower 
percentage of CD3 T cells, shorter telomere length and higher concentrations of 
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Trecs. PBMCs stimulated with phytohemagglutinin (PHA) and assessed for 3H 
incorporation showed a trend towards higher proliferative capacity in children 
who were born with LBW (Raqib, Alam et al. 2007). Most studies in PT and LBW 
infants have largely focused on Ab responses, but a recent study on post-
vaccination responses to inactivated polio vaccination at 2 months of age 
measured T cell responses (Klein, Gans et al. 2010). Even though levels of 
poliovirus type 3-specific memory T cells were comparable at 2 months of age, 
poliovirus type 3-specific proliferation was lower in PT infants compared to term 
infants. At 7 months of age, levels of circulating poliovirus-specific memory T 
cells were lower in PT infants implying a waning immune response in PT infants. 
In addition, at 2 and 7 months of age, levels of CD4+CD69+IFN- + T cells 
induced by staphylococcus enterotoxin B (SEB) stimulation were significantly 
reduced in PT infants compared to term infants (Klein, Gans et al. 2010). This 
study suggests that PT infants may have both vaccine-specific and nonspecific T 
cell deficiencies. 
BCG-induced immunity is 80% efficacious in protecting against severe 
forms of childhood TB, however efficacy against development of adult pulmonary 
TB varies from 0 to 80% (Trunz, Fine et al. 2006). The effect of birth weight and 
maturity on the proliferative capacity of T cells following BCG vaccination has not 
been completely defined, and may be a contributing factor to the variable efficacy 
of BCG. A few studies have looked at purified protein derivative (PPD)-specific 
proliferative responses in these infants. One study measured PBMC 
lymphoproliferation post-BCG vaccination and found no difference in PPD-
specific responses when 30 LBW infants were compared to 56 NBW infants 
(Ferreira, Bunn-Moreno et al. 1996). Mussi-Pinhata et al also measured PBMC 
lymphoproliferation to PPD in a study assessing the effects of intra uterine 
growth restriction (IUGR) on BCG immunogenicity. No differences were found 
between 57 SGA and 52 AGA term infants vaccinated at birth, 3 and 6 months of 
age. Furthermore, no difference was observed in proliferative responses between 
SGA infants vaccinated when they reached a birth weight of 2,500g, compared to 
AGA infants vaccinated at birth (Mussi-Pinhata, Goncalves et al. 1993).  
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Neonatal immunity studies suggest that proliferative responses in LBW 
infants may be functionally immature. However, there is a paucity of data in the 
current literature characterizing vaccine-induced proliferative responses in PT 
and LBW infants. Previous studies have been limited in that a detailed analysis of 
the specific T cell subsets and cytokine-producing capacity of BCG-specific 
proliferating cells in PT and LBW infants has not been performed. In addition, we 
observed in a WB-ICC assay that LBW infants had a lower overall frequency of 
BCG-specific CD4+ T cells expressing IL-2, which may translate into reduced 
proliferative capacity. This prompted us to comprehensively characterize these 
responses in PT and LBW infants.  
In this preliminary study, we aimed, for the first time, to use 
multiparameter flow cytometry and a 6-day PBMC Ki67 proliferation assay with 
intracellular cytokine staining to measure BCG-specific proliferative responses in 
infants stratified by birth weight and maturity. A Ki67 proliferation assay has 
advantages over standard methods of being non-toxic, non-radioactive and 
simple to use (Shedlock, Talbott et al. 2010; Soares, Govender et al. 2010). The 
use of multiparameter flow cytometry in this context would allow the detailed 
study on a single cell basis of Ki67+ proliferating cells expressing cytokines in 
response to BCG stimulation. We hypothesized that BCG vaccination at birth 
induces antigen-specific T cells with a greater proliferative and cytokine 
producing capacity in NBW infants, compared with LBW infants. Measurement of 
BCG-specific proliferative responses in the context of birth weight and maturity 





4.3.1 Flow cytometric detection of proliferating T cells in the Ki67 and Oregon 
Green proliferation assays  
Previously, we showed an alteration in the cytokine production profile of BCG-
specific responses in LBW infants. Proliferation is an important assessment of 
vaccine immunogenicity and T cell function, thus we next assessed the effect of 
birth weight on BCG-specific proliferative responses. In our aim to study the 
proliferative and cytokine producing capacity of BCG-specific T cells in LBW and 
NBW infants in more detail, we required a PBMC proliferation assay to optimally 
measure these responses in cryopreserved cells. We compared a Ki67 
proliferation assay with an Oregon Green (OG)-based dye dilution proliferation 
assay. Ki67 is expressed in the nuclei of actively dividing cells and can thus be 
used as a marker of proliferation, whilst the fluorescence intensity of OG is 
halved with each cell division, thereby allowing measurement of populations of 
proliferating cells (see Materials and Methods, 2.1.2).  
Based on reports of potential OG toxicity to PBMC cultures (Wallace, 
Tario et al. 2008), we first compared the frequency of viable CD3+ T cells from a 
Ki67 proliferation assay with a dye dilution OG proliferation assay. Recovery of 
sufficient numbers of viable cells following long-term storage of cryopreserved 
PBMC would ultimately determine if we could reliably compare different 
outcomes in our study.  
 An aliquot of cryopreserved cells from a 10-week old infant were thawed 
and cultured for 6 days with or without antigen in either a Ki67 proliferation assay 
or OG proliferation assay (see Materials and Methods, 2.2.4). On day 6, cells 
were labeled with the viability dye ViViD to enable identification of viable cells. 
We then analysed cells by multiparameter flow cytometry and a sequential gating 
strategy (Fig. 4.1A) was used to delineate total live CD3+ T cells into different 
subsets (CD4+ and CD8+). Live CD3+ T cells were selected by gating on 
ViViDlow stained cells (Fig. 4.1A). Representative data for proliferating live CD4+ 
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T cells from an OG proliferation assay (Fig. 4.1B) and from a Ki67 proliferation 
assay (Fig. 4.1C) are shown. Gates were based on the unstimulated sample and 
were kept constant for each infant’s corresponding SEB and BCG stimulated 
condition. The percentage of viable cells after 6-day culture for all conditions was 
significantly higher when PBMC were stained on day 6 with Ki67 only, compared 
to cells labeled on day 0 with OG (Fig. 4.1D). These results indicate that labeling 
cryopreserved PBMC with OG may contribute to increased toxicity in the 6-day 
culture, as evidenced by decreased frequencies of live CD3+ T cells on day 6, 
compared to cells incubated in the Ki67 proliferation assay. The Ki67 assay was 
favored as it enabled recovery of a greater percentage of viable cells that could 




Figure 4.1. Flow cytometry gating strategy and analysis of lymphocyte viability in the Ki67 and 
Oregon Green (OG) proliferation assays. Cryopreserved PBMC were thawed and cultured with 
BCG, SEB or medium (UNS; unstimulated) in either a 6-day Ki67 proliferation assay (without 
OG), or a 6-day OG-based proliferation assay (see Materials and Methods, 2.2.5). (A) Gating is 
first performed on singlets then on live lymphocytes by gating on ViViD low CD3+ cells, from which 
total CD3+ T cells are differentiated into CD3+CD8+ and CD3+CD8- T cell subsets. This is 
followed by gating on CD8+ and CD8- OGlow (B) or CD8+ and CD8- Ki67+ (C) proliferating cells. 
CD4+ T cells were defined as CD3+CD8- lymphocytes. Representative data are shown from a 
BCG stimulated sample. (D) Frequency of viable CD3+ T cells gated on ViViDlow CD3+ live cells 
from Ki67 (n=7) and OG (n=14) proliferation assays. The horizontal line represents the median; 
the Mann Whitney test was used for comparisons between two groups. 
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4.3.2 Kinetics of Ki67 expression in proliferating T cells over 6 days  
Next we investigated the kinetics of proliferating cells detected by Ki67 
expression over 6 days in the presence or absence of antigen. Aliquots of 
cryopreserved PBMC from 5 infants were thawed, and cultured for 6 days. Using 
multiparameter flow cytometry we investigated proliferating cells by quantifying 
Ki67 expression in cells from 5 donors harvested on days 2, 4 and 6. The dot 
plots in Fig. 4.2A are representative of proliferating cells detected by intracellular 
Ki67 expression. 
In unstimulated cells, the frequency of proliferating cells detected was low 
on day 2, with a slight increase on day 4 and a peak in proliferation at day 6 (Fig. 
4.2B). Background proliferation on day 6 was an unexpected result, as most 
lymphocytes isolated from peripheral blood are in the resting phase until 
stimulated. Repeated experiments (data not shown) ruled out contamination of 
unstimulated cells. We concluded that long-term cryopreserved infant PBMC 
samples, when thawed and cultured for 6 days in the absence of antigen, may 
spontaneously proliferate and express Ki67 at low levels. We then quantified 
antigen-specific proliferation upon BCG stimulation; specific proliferating cells 
were detected at very low levels on day 2. On day 4 we saw an appreciable 
increase in BCG-specific proliferating cells with peak expression detected on day 
6 (Fig. 4.2C). Although background proliferation was present on day 6 in 
unstimulated cells, BCG-specific cell proliferation was above levels detected in 
unstimulated cells. We observed the same pattern in unstimulated and BCG 
stimulated PBMC cultured over 6 days in an OG assay (data not shown). These 
results together with increased frequencies of live CD3+ T cells we observed on 
day 6 in the Ki67 assay prompted us to continue with this assay to determine the 
effects of birth weight on different outcomes selected in our study. 
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Figure 4.2. Kinetics of Ki67 expression in proliferating T cells over 6 days. Cryopreserved PBMC 
were thawed and cultured with BCG or medium only (unstimulated) in a 6-day Ki67 proliferation 
assay (see Materials and Methods, 2.2.5). Representative dot plots of proliferating CD8-Ki67+ 
live cells from one infant incubated with medium only or BCG and quantified on days 2, 4 and 6 
are shown (A). The frequency of proliferating CD8- Ki67+ live cells incubated with medium only 
(B) or BCG (C) were quantified on days 2, 4 and 6 by multiparameter flow cytometry. CD4+ T 
cells were defined as CD3+CD8- lymphocytes. Data shown are from 5 infants. Dot plots shown 
are from one infant and data are shown as a percentage of CD4+ T cells. 
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4.3.3 Frequency of BCG-specific proliferating T cells in LBW and NBW infants 
To investigate whether the BCG-specific proliferative response was affected by 
birth weight, cryopreserved PBMC from a 6-day Ki67 proliferation assay (see 
Materials and Methods, 2.2.5) were thawed and anlaysed by multiparameter flow 
cytometry. Proliferating cells were detected by quantifying intracellular 
expression of Ki67 in viable CD3+CD8+ and CD3+CD8- (CD4+) lymphocytes. 
We compared BCG-specific CD4+ and CD8+ T cell responses in 40 infants 
grouped categorically as either LBW (n=20) or NBW (n=20) (Fig. 4.3). No 
difference was demonstrated in the frequency of proliferating BCG-specific (Fig. 




Figure 4.3. Proliferative response of BCG-specific Ki67+CD4+ and CD8+ T cells in LBW (n=20) 
and NBW (n=20) infants. Proliferative response is expressed as a stimulation index (SI). The 
horizontal line represents the median. Statistical differences between the proliferative BCG-
specific T cell responses were determined by the Mann Whitney test. 
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After assessing the effect of birth weight categorically, we next 
investigated the effect of birth weight as a continuous variable on the frequency 
of proliferating cells. We found no correlation between the frequency of either 
BCG-specific CD4+ or CD8+ T cells expressing Ki67 and birth weight in 40 
infants (Fig. 4.4). Our results indicate that BCG and SEB induce substantial 
proliferation of T cells, but that birth weight does not affect the ability of these 
cells to proliferate and express Ki67. 
 
 
Figure 4.4. Correlation between BCG-specific T cell proliferation and birth weight. (A) Correlation 
between BCG-specific Ki67+CD4+ T cell expression and birth weight (n=40). (B) Correlation 
between BCG-specific Ki67+CD8+ T cell expression and birth weight (n=40). Statistical analyses 
were determined by the Spearman test. 
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4.3.4 Effect of birth weight on the total cytokine producing capacity of Ki67+ 
BCG-specific T cells 
The cytokine producing capacity of BCG-specific Ki67+ proliferating T cells from 
a 6-day Ki67 proliferation assay was assessed by adding PMA/I for the last 5 
hours of culture, followed by analysis by flow cytometry (see Materials and 
Methods, 2.2.5). Short-term restimulation with PMA/I stimulates cytokine 
production, providing further information on the functional capacity within the 
population of antigen-specific, proliferating T cells. Although PMA/I restimulation 
on day 6 was able to induce some cytokine production by cells incubated without 
antigen from day 0 (Unstimulated), this was low compared to the appreciable 
amounts IL-2, IFN-  or TNF-  produced by proliferating BCG-specific Ki67+ 
CD4+ T cells in LBW and NBW infants (Fig. 4.5A). All infants had a proliferative 
response to the positive control, SEB. We excluded infants who failed to meet 
criteria for a CD4+ BCG-specific proliferative response (n=2; see Materials and 
Methods, 2.2.8). Within the total CD4 T cell population, we compared the total 
cytokine expression of proliferating BCG-specific CD4 T cells expressing either 
IL-2, IFN-  or TNF-  cytokines between LBW and NBW infants. There were no 
differences in the total CD4+ T cell expression of any of the cytokines by birth 
weight (NBW, n=18 and LBW, n=18)  (Fig. 4.5B). These results indicate that total 






















Figure 4.5. Cytokine production capacity of BCG-specific proliferating CD4+ T cells. 
Cryopreserved PBMC were cultured for 6 days with BCG, SEB or medium (UNS; unstimulated) 
(see Materials and Methods, 2.2.5). To detect cytokine expression, cells were restimulated for 5 
hrs on day 6 with PMA and ionomycin (PMA/I) and analyzed by flow cytometry. Cells gated on 
proliferating CD3+CD8- Ki67+ live cells were differentiated into T cells expressing combinations 
of IL-2, IFN-  or TNF- . CD4+ T cells were defined as CD3+CD8- lymphocytes. (A) 
Representative dot plots of cytokine expressing cells gated on live CD4+ proliferating cells in one 
LBW and NBW infant are shown. Percentages shown on the plots are prior to subtraction of 
cytokine production in the PMA/I negative control sample. The percentage of BCG-specific CD4+ 
T cells expressing cytokines in LBW (n=18) and NBW (n=18) infants is shown in (B). The data is 
shown as the frequency of grandparent (see Materials and Methods, 2.2.7). The horizontal line 
represents the median and the boxes represent the interquartile range. Data shown in (B) are 
after background subtraction of the PMA/I negative control sample (see Materials and Methods, 
2.2.8). Statistical analyses were determined by the Mann Whitney test.  
 88 
4.3.5 Effect of birth weight on the cytokine expression profiles of proliferating 
BCG-specific T cells 
After assessing total cytokine expression in the analysis above, we next 
investigated the cytokine expression profile of individual proliferating T cells 
restimulated with PMA/I. Using multiparameter flow cytometry we CD4+ T cells 
and their capacity to express combinations of IL-2, IFN-  or TNF- . After 
excluding infants who failed to meet criteria for a CD4+ BCG-specific proliferative 
response (n=2; see Materials and Methods, 2.2.8), we then compared cytokine 
expression between LBW and NBW infants. 
Within the total T cell population, we compared the frequencies (Fig. 4.6A) 
and the proportions (Fig. 4.6B) of proliferating, cytokine producing BCG-specific 
CD4+ T cells. The most dominant response was that of BCG-specific CD4+ T 
cells co-expressing IFN-  and TNF- . Short-term PMA/I restimulation did not 
induce any cytokine expression in a large proportion of BCG-specific T cells, and 
no difference was observed between LBW and NBW infants (right panels of Fig. 
4.6). Similar frequencies and proportions (left panels of Fig. 4.6A and B, 
respectively) of T cell subsets expressing 7 different combinations of IL-2, IFN-  
or TNF-  were observed in LBW and NBW infants. We concluded that the 
magnitude and qualitative response as measured by a Ki67 proliferation assay is 
not affected by birth weight.  
 89 
 
Figure 4.6. The frequency (A) and proportion (B) of proliferating BCG-specific CD4+ T cells 
expressing combinations of IL-2, IFN-  or TNF-  cytokines in LBW and NBW infants. Data shown 
are after background subtraction of the PMA/I negative control sample, and only infants who met 
criteria for a positive response and minimum numbers of viable CD3+ cells are shown (LBW, 
n=18 and NBW, n=18) (see Materials and Methods, 2.2.8). The data is shown as the frequency of 
grandparent (see Materials and Methods, 2.2.7). CD4+ T cells were defined as CD3+CD8- 
lymphocytes. The horizontal line represents the median and the boxes represent the interquartile 
range. Each pie is divided into 4 slices that represent the median proportion of the total BCG-
specific CD4+ T cell response, a slice each for proliferating T cells that are not expressing any 
cytokines, or a combination of 3, 2 or 1 cytokine only (B). Statistical analyses were determined by 
the Mann Whitney test.  
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4.3.6 Effect of birth weight on cytokine expression of proliferating BCG-specific 
CD8 T cells 
After assessing the effect of birth weight on cytokine expression of BCG-specific 
proliferating CD4+ T cells, we next performed a similar analysis of CD8+ T cell 
responses. We used multiparameter flow cytometry to measure the cytokine 
producing capacity of BCG-specific Ki67+ proliferating T cells restimulated with 
PMA/I from a 6-day Ki67 proliferation assay. Proliferating BCG-specific Ki67+ 
CD8+ T cells expressing appreciable amounts IL-2, IFN-  or TNF-  above 
background were detected in LBW and NBW infants (Fig. 4.7A). All infants had a 
proliferative response to the positive control, SEB. We excluded infants who 
failed to meet criteria for a CD8+ BCG-specific proliferative response (n=4; see 
Materials and Methods, 2.2.8). There was no difference in the total cytokine 
expression of proliferating BCG-specific CD8 T cells between LBW and NBW 


























Figure 4.7. Cytokine production capacity of BCG-specific proliferating CD8+ T cells. 
Cryopreserved PBMC were cultured for 6 days with BCG, SEB or medium (UNS; unstimulated), 
restimulated for 5 hrs on day 6 PMA/I and analyzed by flow cytometry (see Materials and 
Methods, 2.2.5). Cells gated on proliferating CD3+CD8+ Ki67+ live cells were differentiated into T 
cells expressing combinations of IL-2, IFN-  or TNF- . (A) Representative dot plots of cytokine 
expressing cells gated on live CD3+CD8+ proliferating cells in one LBW and NBW infant are 
shown. Percentages shown on the plots are prior to subtraction of cytokine production in the 
PMA/I negative control sample. (B) Frequency of BCG-specific CD8+ T cells that are proliferating 
and expressing cytokines in LBW and NBW infants. The data is shown as the frequency of 
grandparent (see Materials and Methods, 2.2.7). The horizontal line represents the median and 
the boxes represent the interquartile range. There was no statistical difference as determined by 
the Mann Whitney test. 
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We next performed a detailed analysis of the cytokine expression profile of 
individual proliferating CD8+ T cells found in 7 distinct subsets expressing 
combinations of IL-2, IFN-  or TNF-  (left panels, Fig. 4.8). We compared the 
frequency (left panels, Fig. 4.8A) and proportion (left panels, Fig. 4.8B) of 
proliferating BCG-specific CD8+ T cells expressing all combinations of IL-2, IFN-
, TNF- , and found no difference between NBW and LBW infants. The main 
populations of cells expressed either IL-2 or IFN-  only. However the majority of 
CD8 T cells did not express any cytokine at all, and no difference in this subset 
was found between LBW and NBW infants (right panels of Fig. 4.8A and Fig. 
4.8B). These results indicate that the magnitude and quality of the proliferating 
BCG-specific CD8+ T cell response is not affected by birth weight as measured 




Figure 4.8. The frequency (A) and proportion (B) of BCG-specific CD8+ T cells that are 
proliferating and expressing combinations of IL-2, IFN-  or TNF-  cytokines in LBW and NBW 
infants. Data shown are after background subtraction of the PMA/I negative control sample, and 
only infants who met criteria for a positive response and minimum numbers of viable CD3+ cells 
are shown (LBW, n=16 and NBW, n=16) (see Materials and Methods, 2.2.8). The data is shown 
as the frequency of grandparent (see Materials and Methods, 2.2.7). The horizontal line 
represents the median and the boxes represent the interquartile range. Each pie is divided into 4 
slices that represent the median proportion of the total BCG-specific CD8+ T cell response, a 
slice each for T cells that are not expressing any cytokines, or a combination of 3, 2 or 1 cytokine 





In the previous chapter, we showed differences in BCG immunogenicity by birth 
weight on a single cell basis using a WB-ICC assay and multiparameter flow 
cytometry. This short-term assay measured cytokine production ex vivo, which is 
only one aspect of cellular immune responses. To gain a greater comprehension 
of BCG-induced immunity, it is important to further characterize immune 
responses in susceptible populations such as PT and LBW infants. We thus 
measured the proliferative potential and cytokine producing capacity of BCG-
specific T cells, critical functions that may be affected by birth weight. Evidence 
of neonatal functional immaturities and the lack of previous detailed studies on 
BCG-specific proliferative responses prompted us to perform this study. We used 
a 6-day Ki67 lymphoproliferation assay and multiparameter flow cytometry, a 
more sensitive and specific assay that could measure BCG-specific responses 
on a single cell basis. To the best of our knowledge this is the first time such 
assay systems have been used to characterise BCG specific proliferative 
responses in LBW infants. We report that following BCG vaccination, BCG-
specific proliferative responses were not affected by birth weight or maturity.  
 We complemented our initial WB-ICC results by measuring the ability of 
lymphocytes to proliferate and express cytokines in response to BCG stimulation 
in vitro. We used a 6-day Ki67 proliferation assay that has been shown to be 
antigen specific, reproducible and comparable to other conventional methods 
such as dye dilution of Oregon Green (OG) (Shedlock, Talbott et al. 2010; 
Soares, Govender et al. 2010). Ki67 is a nuclear protein that can be used as a 
marker of proliferation in vitro as it is upregulated and expressed in actively 
dividing cells but not in resting cells (Jeurink, Vissers et al. 2008; Soares, 
Govender et al. 2010). During long-term culture, cell death occurs thus we 
incorporated a viability dye in the assay enabling the differentiation of live cells 
from dead cells by flow cytometry. The Ki67 proliferation assay has been studied 
in detail before (Shedlock, Talbott et al. 2010; Soares, Govender et al. 2010) and 
we chose this assay over an OG proliferation assay as we found it to be less 
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toxic. Thus we were able to exclude dead cell artifacts, and to measure sufficient 
numbers of proliferating cells isolated and expanded from the small volume of 
blood that we could collect from 10-week-old infants. 
Similar to a study by Soares et al, we used multiparameter flow cytometry 
to quantify the kinetics of Ki67 expression in live proliferating T cells over 6 days 
(Soares, Govender et al. 2010). However, in contrast to their findings, we found 
high background frequencies of Ki67+ proliferating T cells in our unstimulated 
samples on day 6 of the assay. This may be due to difference in methodology, as 
we used cryopreserved infant PBMCs isolated from peripheral blood, whilst 
Soares et al used fresh whole blood from either adults or toddlers. Jeurink et al 
has reported a difference in cytokine production of Ki67+ proliferating cells in 
cryopreserved PBMC compared to freshly isolated PBMC.  PMA and calcium 
ionophore (Ca-I) stimulated cells expressing Ki67 had reduced levels of IL-4, IL-
13 and IL-1-  after cryopreservation compared to freshly isolated cells (Jeurink, 
Vissers et al. 2008). In addition, the high frequencies we observed could be due 
to the high rate of cell turn over in neonates (Hassan and Reen 2001; Schonland, 
Zimmer et al. 2003; Szabolcs, Park et al. 2003). However, the background Ki67 
expression did not impact on our results, as after BCG stimulation and 6-day 
culture, BCG-specific Ki67+ proliferative responses were higher than 
background.  
In comparison, NBW and LBW infants had similar frequencies of BCG-
specific proliferating T cells and we found no association with birth weight. These 
results are consistent with a previous study by Ferreira et al, who reported that 
birth weight did not affect the ability of PPD-specific cells to proliferate (Ferreira, 
Bunn-Moreno et al. 1996). All infants responded equally to SEB stimulation 
showing that global T cell proliferation was functional in this cohort. This is in 
contrast with a study by Raqib et al that found a trend towards greater 
proliferative responses to PHA in LBW infants compared to NBW infants, whilst a 
study by Klein et al suggested reduced proliferative responses to poliovirus type 
3 in PT infants compared to term infants (Raqib, Alam et al. 2007; Klein, Gans et 
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al. 2010). Use of cryopreserved PBMCs in our study compared to freshly isolated 
PBMC in Klein et al’s study may explain the contrasting results. On the other 
hand, Raqib et al’s cohort consisted of children who were formerly LBW and 
proliferation was assessed by 3H uptake in 3-day PHA-stimulated cells. These 
differences in methodology compared to our BCG-stimulated 6-day Ki67 
proliferation assay may be the underlying reasons for our contrasting results.  
The functional capacity of BCG-specific proliferating cells from a 6-day 
Ki67 proliferation assay were determined by polyclonal re-stimulation with PMA/I 
during the last 5 hours of culture. PMA/I induces T cell activation and cytokine 
production by directly activating protein kinase C-  in a TCR independent 
process. This reflects the intrinsic ability of a T cell to proliferate and produce 
cytokines regardless of TCR expression (Kim, Lancki et al. 1989; Kim, St John et 
al. 2009). We measured the expression of IFN- , IL-2 and TNF- , cytokines that 
we found to differ by birth weight as measured by a WB-ICC assay and 
multiparameter flow cytometry (see Chapter 2). 
We measured the total expression and the capacity to express 
combinations of the cytokines IFN- , IL-2 or TNF-  in BCG-specific proliferating 
cells. Birth weight did not affect the ability of BCG-specific cells to proliferate and 
express cytokines, in particular IL-2 which is important for immunological memory 
(Chaplin 2010). These cytokines, as discussed in previous chapters, are induced 
upon BCG vaccination and play important roles in host defense against TB 
disease. 
These preliminary results do not support our hypothesis that BCG 
vaccination at birth induces antigen-specific T cells with a greater proliferative 
and cytokine producing capacity in NBW infants compared with LBW infants. 
BCG strongly activates DCs, and unlike other childhood vaccines, seems to be 
able to overcome immaturities in the neonatal immune system that are mainly of 
a Th2 phenotype by skewing them towards a Th1 phenotype (Marchant and 
Goldman 2005). This may be a reason why differences were not seen between 
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LBW and NBW infants. This potential masking of responses as a result of BCG 
induced innate cell activation may not be seen if individual mycobacterial 
antigens (Ags) such as M.tb peptides or recombinant proteins had been used to 
stimulate cells. 
Our preliminary results suggest that birth weight at the time of vaccination 
does not affect the magnitude and quality of the BCG-induced proliferative 
responses in a Ki67 assay. Due to the small sample size, we were unable to 
determine the effects of gestational age, size for GA or gender on BCG-specific 
proliferative responses. We thus propose that further studies should be 
performed in larger cohorts to determine the effects of these host factors on 
BCG-specific proliferative responses. In addition, the persistence of the 
proliferative responses we measured should be further investigated in 
longitudinal studies. The importance of this is highlighted by Kagina et al’s study 
on delaying BCG vaccination from birth to 10 weeks. Differences between birth 
vaccinated infants and those vaccinated at 10 weeks were most significant at 1 
year of age (Kagina, Abel et al. 2009). In particular, the frequency of 
polyfunctional BCG-specific T cells was greater in the delayed group (Kagina, 
Abel et al. 2009) and it may be possible that in our study, the proliferative 
capacity of BCG-specific T cells in LBW infants is impaired at later time points. 
Future studies will ultimately lead to optimal vaccination strategies in susceptible 
populations such as PT and LBW infants. This is important, as the basis of 
immunisation is to induce memory cells, which upon exposure to the actual 
pathogen will proliferate more rapidly and effectively respond to provide 










Overall, we have shown that LBW infants may have an altered immune response 
to BCG. In particular, using a WB-ICC assay, we found that LBW infants had a 
lower proportion of polyfunctional BCG-specific CD4+ T cells and corresponding 
higher proportions of single cytokine-producing CD4+ T cells expressing IFN-  
only, compared to NBW infants. No differences were found in the proliferative 
potential of BCG-specific T cells from a 6-day Ki67 proliferation assay. In 
addition, most cytokine expression patterns of specific cells were not affected by 
BW, GA, size for GA or gender. The clinical and biological significance of our 
results is unknown. In the absence of large-scale efficacy trials, our results are 
too preliminary to suggest that optimal protection afforded by BCG vaccination 
can be obtained by vaccinating all infants at birth regardless of birth weight or 
gestational age. Our results are also presented in light of several limitations that 
we acknowledge.  
  The risk factors that may contribute to IUGR and LBW are numerous 
(Valero De Bernabe, Soriano et al. 2004) and were not controlled for in our study. 
Our study participants come from the rural Worcester area of the Western Cape 
and data is available for this region, which should provide a basic socio economic 
history. Infants enrolled in our study were born predominantly to mixed race 
(“colored”) mothers who were low-income workers. The Western Cape is a wine-
producing region and due to maternal alcohol consumption, certain rural areas 
have reported the highest incidence of fetal alcohol syndrome (FAS) ever 
worldwide (May, Gossage et al. 2005; May, Gossage et al. 2007). In rural areas 
up to 51% of mothers abuse alcohol during pregnancy and in addition, an 
estimated 48% of mixed race adults (>18 years) in the Western Cape region of 
South Africa smoke tobacco (Reddy, Meyer-Weitz et al. 1996; May, Gossage et 
al. 2005). Ethnicity, low socioeconomic level, maternal smoking and FAS are 
possible risk factors for LBW (Valero De Bernabe, Soriano et al. 2004), and any 
of these may be confounders that could have potentially affected BCG-induced T 
cell responses in our study participants.  
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 Our study participants were formerly enrolled as part of a larger 
randomised control trial (RCT; n=11,670). As part of the RCT, unhealthy infants 
were excluded. It is possible that exclusion of ill or symptomatic infants resulted 
in potential selection for a healthier population of LBW infants, as most LBW 
infants are generally more susceptible to infection and therefore more likely to 
have been excluded at enrolment. More differences may have been observed if 
these infants were included in this study. The blood products we used in this 
study had been collected in the RCT investigating the incidence of TB over 2 
years in infants vaccinated at birth intradermally or percutaneously with 
Japanese BCG. Our study participants did not develop TB over a 2-year follow 
up and were thus excluded from the RCT. However as part of the RCT, whole 
blood collected was immediately stimulated and processed in a WB-ICC and 
cryopreserved. Therefore, we had no control in this study over the antigen 
stimulus used, and upon thawing the cryopreserved whole blood samples we 
could not explore any other Ags and mitogens. On the other hand, multiple 
aliquots of PBMC were collected and cryopreserved from each infant enrolled. 
Production of cytokines following short-term stimulation of these PBMC with 
mycobacterial antigens other than BCG, such as Mtb protein or peptides, could 
have been performed. These assays could have been complemented by 
assessment of proliferation. Soluble cytokines levels from the supernatant of 
these cultured PBMC could have been measured as well. These different assays 
would be of interest in future studies on BCG immunogenicity in PT and LBW 
infants.     
Other aspects of BCG-induced immunity may be affected by birth weight 
and maturity. In this study, we focused only on the cytokines IFN- , TNF- , IL-2, 
and IL-17. Various other cytokines, Tregs, δ T cells and memory T cell 
phenotype induced by BCG vaccination may be differentially affected by birth 
weight and maturity, and would be interesting to investigate in future studies. In 
addition, host innate immunity also plays an important role in BCG-induced 
immunity, although the analysis of multiple immune mechanisms was beyond the 
scope of this study. Thus our aim was focused on certain aspects of T cell 
 101 
immunity and on measuring BCG-induced T cell responses. In this study it would 
have been interesting to correlate proliferation and whole blood assay cytokine 
responses. Due to the limited availability of stored PBMC and whole blood of 
each enrolled infant, both assays were performed only a small number of infants, 
and we were thus unable to directly compare these two assays in the same 
infants. 
Our study highlights the complexity of birth weight and maturity on the 
immune response to BCG vaccination. This represents the first detailed analysis 
of the functional capacity of BCG-induced T cell responses in healthy PT and 
LBW infants. These data are currently lacking in the literature, especially in highly 
endemic TB areas such as South Africa. Statistical correction for multiple 
comparisons was not performed and it is possible that significance will not be 
maintained after such correction.  Although we cannot draw firm conclusions, our 
preliminary findings raise the possibility that healthy PT and LBW infants may not 
develop optimal BCG-induced immunity. However, as immune correlates of 
protection against TB have not been defined to date, we suggest caution in 
interpreting our preliminary results, which have unknown implications in terms of 
protection against TB disease. As shown in a recent human study, the quality of 
the polyfunctional BCG-specific CD4+ T cell response that we found to be 
elevated in NBW infants may not be an immune correlate of protection (Kagina, 
Abel et al. 2010). Future studies confirming our results, as well as optimization of 
vaccine strategies and efficacy trials in PT and LBW infants are required before 
current BCG vaccination policies are altered. Future studies may potentially 
improve the efficacy of BCG. Our study has potentially important implications for 
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